株探米国株
英語
エドガーで原本を確認する
0001907982December 312023Q2falsehttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent00019079822023-01-012023-06-300001907982us-gaap:CommonStockMember2023-01-012023-06-300001907982us-gaap:WarrantMember2023-01-012023-06-3000019079822023-08-07xbrli:shares00019079822023-06-30iso4217:USD00019079822022-12-31iso4217:USDxbrli:shares00019079822023-04-012023-06-3000019079822022-04-012022-06-3000019079822022-01-012022-06-300001907982srt:ScenarioPreviouslyReportedMemberus-gaap:PreferredStockMember2021-12-310001907982srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember2021-12-310001907982srt:ScenarioPreviouslyReportedMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001907982srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2021-12-310001907982srt:ScenarioPreviouslyReportedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001907982srt:ScenarioPreviouslyReportedMember2021-12-310001907982us-gaap:PreferredStockMembersrt:RestatementAdjustmentMember2021-12-310001907982srt:RestatementAdjustmentMemberus-gaap:CommonStockMember2021-12-310001907982srt:RestatementAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001907982srt:RestatementAdjustmentMemberus-gaap:RetainedEarningsMember2021-12-310001907982srt:RestatementAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001907982srt:RestatementAdjustmentMember2021-12-310001907982us-gaap:PreferredStockMember2021-12-310001907982us-gaap:CommonStockMember2021-12-310001907982us-gaap:AdditionalPaidInCapitalMember2021-12-310001907982us-gaap:RetainedEarningsMember2021-12-310001907982us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100019079822021-12-310001907982us-gaap:CommonStockMember2022-01-012022-06-300001907982us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001907982us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001907982us-gaap:RetainedEarningsMember2022-01-012022-06-300001907982us-gaap:PreferredStockMember2022-06-300001907982us-gaap:CommonStockMember2022-06-300001907982us-gaap:AdditionalPaidInCapitalMember2022-06-300001907982us-gaap:RetainedEarningsMember2022-06-300001907982us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000019079822022-06-300001907982us-gaap:CommonStockMember2022-12-310001907982us-gaap:AdditionalPaidInCapitalMember2022-12-310001907982us-gaap:RetainedEarningsMember2022-12-310001907982us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001907982us-gaap:CommonStockMember2023-01-012023-06-300001907982us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001907982us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001907982us-gaap:RetainedEarningsMember2023-01-012023-06-300001907982us-gaap:CommonStockMember2023-06-300001907982us-gaap:AdditionalPaidInCapitalMember2023-06-300001907982us-gaap:RetainedEarningsMember2023-06-300001907982us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30qbts:facility0001907982srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-04-012023-06-300001907982srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-01-012023-06-300001907982srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-04-012022-06-300001907982srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-01-012022-06-300001907982qbts:TermLoanMemberus-gaap:LineOfCreditMember2023-04-130001907982qbts:TermLoanMemberqbts:DebtInstrumentTrancheOneMemberus-gaap:LineOfCreditMember2023-04-130001907982qbts:DebtInstrumentTrancheThreeMemberqbts:TermLoanMemberus-gaap:LineOfCreditMember2023-04-1300019079822022-06-16xbrli:pure0001907982qbts:TermLoanMemberus-gaap:SubsequentEventMemberus-gaap:LineOfCreditMemberqbts:DebtInstrumentTrancheTwoMember2023-07-132023-07-1300019079822023-02-130001907982us-gaap:SubsequentEventMember2023-07-242023-08-070001907982qbts:TermLoanMemberus-gaap:LineOfCreditMember2023-04-132023-04-130001907982qbts:TermLoanMemberus-gaap:LineOfCreditMember2023-01-012023-06-300001907982qbts:TermLoanMemberus-gaap:LineOfCreditMember2023-04-012023-06-300001907982us-gaap:FairValueInputsLevel1Memberqbts:PublicWarrantsMember2023-06-300001907982us-gaap:FairValueInputsLevel2Memberqbts:PrivateWarrantsMember2023-06-300001907982qbts:TermLoanMemberus-gaap:LineOfCreditMemberus-gaap:FairValueInputsLevel3Member2023-06-3000019079822022-08-050001907982qbts:DCPMCapitalIncClassACommonStockMember2022-08-052022-08-050001907982qbts:DCPMCapitalIncClassACommonStockMemberqbts:DPCMCapitalIncStockholdersMember2022-08-052022-08-050001907982qbts:DCPMCapitalCorpIncClassBCommonStockMemberqbts:DPCMCapitalIncStockholdersMember2022-08-052022-08-050001907982qbts:DCPMCapitalCorpIncClassBCommonStockMemberqbts:DPCMCapitalIncStockholdersMember2022-08-050001907982qbts:DWaveSystemsIncStockholdersMember2022-08-052022-08-0500019079822022-08-052022-08-050001907982us-gaap:PrivatePlacementMember2022-08-052022-08-0500019079822022-08-020001907982qbts:QCaaSMember2023-04-012023-06-300001907982qbts:QCaaSMember2022-04-012022-06-300001907982qbts:ProfessionalServicesMember2023-04-012023-06-300001907982qbts:ProfessionalServicesMember2022-04-012022-06-300001907982us-gaap:ProductAndServiceOtherMember2023-04-012023-06-300001907982us-gaap:ProductAndServiceOtherMember2022-04-012022-06-300001907982us-gaap:TransferredOverTimeMember2023-04-012023-06-300001907982us-gaap:TransferredOverTimeMember2022-04-012022-06-300001907982us-gaap:TransferredAtPointInTimeMember2023-04-012023-06-300001907982us-gaap:TransferredAtPointInTimeMember2022-04-012022-06-300001907982qbts:QCaaSMember2023-01-012023-06-300001907982qbts:QCaaSMember2022-01-012022-06-300001907982qbts:ProfessionalServicesMember2023-01-012023-06-300001907982qbts:ProfessionalServicesMember2022-01-012022-06-300001907982us-gaap:ProductAndServiceOtherMember2023-01-012023-06-300001907982us-gaap:ProductAndServiceOtherMember2022-01-012022-06-300001907982us-gaap:TransferredOverTimeMember2023-01-012023-06-300001907982us-gaap:TransferredOverTimeMember2022-01-012022-06-300001907982us-gaap:TransferredAtPointInTimeMember2023-01-012023-06-300001907982us-gaap:TransferredAtPointInTimeMember2022-01-012022-06-300001907982country:US2023-04-012023-06-300001907982country:US2022-04-012022-06-300001907982country:JP2023-04-012023-06-300001907982country:JP2022-04-012022-06-300001907982country:DE2023-04-012023-06-300001907982country:DE2022-04-012022-06-300001907982country:CH2023-04-012023-06-300001907982country:CH2022-04-012022-06-300001907982country:GB2023-04-012023-06-300001907982country:GB2022-04-012022-06-300001907982qbts:OtherGeographicalAreasMember2023-04-012023-06-300001907982qbts:OtherGeographicalAreasMember2022-04-012022-06-300001907982country:US2023-01-012023-06-300001907982country:US2022-01-012022-06-300001907982country:JP2023-01-012023-06-300001907982country:JP2022-01-012022-06-300001907982country:DE2023-01-012023-06-300001907982country:DE2022-01-012022-06-300001907982country:CH2023-01-012023-06-300001907982country:CH2022-01-012022-06-300001907982country:GB2023-01-012023-06-300001907982country:GB2022-01-012022-06-300001907982qbts:OtherGeographicalAreasMember2023-01-012023-06-300001907982qbts:OtherGeographicalAreasMember2022-01-012022-06-300001907982us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberqbts:CustomerAMember2023-04-012023-06-300001907982us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberqbts:CustomerAMember2022-04-012022-06-300001907982qbts:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001907982qbts:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001907982qbts:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001907982qbts:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001907982us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberqbts:CustomerAMember2023-01-012023-06-300001907982us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberqbts:CustomerAMember2022-01-012022-06-300001907982qbts:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001907982qbts:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001907982qbts:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001907982qbts:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001907982us-gaap:AccountsReceivableMemberqbts:TwoCustomersMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001907982qbts:FourCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-3000019079822022-01-012022-12-3100019079822023-07-012023-06-3000019079822023-01-012022-12-310001907982us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-06-300001907982us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001907982qbts:LabEquipmentMember2023-06-300001907982qbts:LabEquipmentMember2022-12-310001907982us-gaap:ComputerEquipmentMember2023-06-300001907982us-gaap:ComputerEquipmentMember2022-12-310001907982us-gaap:LeaseholdImprovementsMember2023-06-300001907982us-gaap:LeaseholdImprovementsMember2022-12-310001907982us-gaap:FurnitureAndFixturesMember2023-06-300001907982us-gaap:FurnitureAndFixturesMember2022-12-310001907982us-gaap:ConstructionInProgressMember2023-06-300001907982us-gaap:ConstructionInProgressMember2022-12-310001907982srt:NorthAmericaMember2023-06-300001907982srt:NorthAmericaMember2022-12-310001907982us-gaap:NotesPayableOtherPayablesMemberqbts:SIFLoanMember2023-06-300001907982us-gaap:NotesPayableOtherPayablesMemberqbts:SIFLoanMember2022-12-310001907982us-gaap:NotesPayableOtherPayablesMemberqbts:TPCGovernmentLoansMember2023-06-300001907982us-gaap:NotesPayableOtherPayablesMemberqbts:TPCGovernmentLoansMember2022-12-310001907982qbts:TermLoanMemberus-gaap:LineOfCreditMember2023-06-300001907982qbts:TermLoanMemberus-gaap:LineOfCreditMember2022-12-310001907982us-gaap:NotesPayableOtherPayablesMemberqbts:DirectorsAndOfficersInsuranceFinancingMember2023-06-300001907982us-gaap:NotesPayableOtherPayablesMemberqbts:DirectorsAndOfficersInsuranceFinancingMember2022-12-310001907982us-gaap:NotesPayableOtherPayablesMemberqbts:OtherLoansMember2023-06-300001907982us-gaap:NotesPayableOtherPayablesMemberqbts:OtherLoansMember2022-12-310001907982us-gaap:NotesPayableOtherPayablesMemberqbts:SIFLoanMember2020-11-20iso4217:CAD0001907982us-gaap:NotesPayableOtherPayablesMemberqbts:SIFLoanMember2020-11-202020-11-200001907982us-gaap:NotesPayableOtherPayablesMemberqbts:SIFLoanMember2023-01-012023-06-300001907982qbts:TermLoanMemberus-gaap:LineOfCreditMemberqbts:DebtInstrumentRepaymentPeriodOneMember2023-04-132023-04-130001907982qbts:DebtInstrumentRepaymentPeriodTwoMemberqbts:TermLoanMemberus-gaap:LineOfCreditMember2023-04-132023-04-130001907982qbts:TermLoanMemberqbts:DebtInstrumentRepaymentPeriodThreeMemberus-gaap:LineOfCreditMember2023-04-132023-04-130001907982qbts:TermLoanMemberus-gaap:LineOfCreditMemberqbts:DebtInstrumentTrancheTwoMember2023-04-130001907982qbts:PublicWarrantsMember2022-08-052022-08-050001907982qbts:PrivateWarrantsMember2022-08-052022-08-05qbts:day0001907982srt:AffiliatedEntityMember2022-12-310001907982srt:AffiliatedEntityMember2022-01-012023-06-300001907982srt:AffiliatedEntityMember2023-06-300001907982us-gaap:BeneficialOwnerMember2023-01-012023-06-300001907982us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001907982us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-01-012023-06-300001907982us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-01-012023-06-300001907982us-gaap:RestrictedStockUnitsRSUMember2022-12-310001907982us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001907982us-gaap:RestrictedStockUnitsRSUMember2023-06-300001907982us-gaap:EmployeeStockMember2022-08-310001907982us-gaap:EmployeeStockMember2022-08-012022-08-310001907982us-gaap:EmployeeStockMember2023-06-300001907982us-gaap:EmployeeStockMember2023-04-012023-06-300001907982us-gaap:EmployeeStockMember2023-01-012023-06-300001907982us-gaap:CostOfSalesMember2023-04-012023-06-300001907982us-gaap:CostOfSalesMember2022-04-012022-06-300001907982us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001907982us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001907982us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001907982us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001907982us-gaap:SellingAndMarketingExpenseMember2023-04-012023-06-300001907982us-gaap:SellingAndMarketingExpenseMember2022-04-012022-06-300001907982us-gaap:CostOfSalesMember2023-01-012023-06-300001907982us-gaap:CostOfSalesMember2022-01-012022-06-300001907982us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001907982us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001907982us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001907982us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001907982us-gaap:SellingAndMarketingExpenseMember2023-01-012023-06-300001907982us-gaap:SellingAndMarketingExpenseMember2022-01-012022-06-300001907982qbts:PreferredStockWarrantsMember2020-11-300001907982qbts:PreferredStockWarrantsMember2020-08-130001907982qbts:PublicWarrantsMemberus-gaap:WarrantMember2023-01-012023-06-300001907982qbts:PublicWarrantsMemberus-gaap:WarrantMember2022-01-012022-06-300001907982us-gaap:WarrantMemberqbts:PrivateWarrantsMember2023-01-012023-06-300001907982us-gaap:WarrantMemberqbts:PrivateWarrantsMember2022-01-012022-06-300001907982qbts:PreferredStockWarrantsMember2023-01-012023-06-300001907982qbts:PreferredStockWarrantsMember2022-01-012022-06-300001907982us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001907982us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001907982us-gaap:SubsequentEventMember2023-07-130001907982us-gaap:SubsequentEventMember2023-07-200001907982qbts:TermLoanMemberus-gaap:SubsequentEventMemberus-gaap:LineOfCreditMember2023-07-202023-07-20
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 10-Q
________________________
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ and ____________
Commission file number 001-41468

________________________
D-WAVE QUANTUM INC.
(Exact name of registrant as specified in its charter)
________________________
Delaware
 88-1068854
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
3033 Beta Avenue, Burnaby, British Columbia, Canada
V5G 4M9
(Address of Principal Executive Offices)
(Zip Code)
(604) 630-1428
Registrant's telephone number, including area code
(Former name, former address and former fiscal year, if changed since last report)
________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.0001 per share QBTS New York Stock Exchange
Warrants, each whole warrant exercisable for 1.4541326 shares of common stock at an exercise price of $11.50 QBTS.WT New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes   x    No   o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x   No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer
 o
Non-accelerated filer x
Smaller reporting company
 x
Emerging growth company
 x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

APPLICABLE ONLY TO CORPORATE ISSUERS:
As of August 7, 2023, the registrant had 98,902,073 shares of common stock at par value $0.0001 outstanding. In addition, there were 46,550,462 exchangeable shares outstanding as of August 7, 2023, which are convertible into shares of common stock on a one for one basis at any time for no consideration.





Table of Contents
Table of Contents
Page
5
35
2
Table of Contents
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Certain statements in this Quarterly Report on Form 10-Q (this “Report”) and in documents incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1933, as amended. Unless otherwise indicated or the context otherwise requires, all references in this Report to the terms “D-Wave” and the “Company” refer to D-Wave Quantum Inc., together with its subsidiaries. Our forward-looking statements include, but are not limited to, statements regarding D-Wave and D-Wave’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “believe”, “may”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “anticipate”, “trend”, “believe”, “estimate”, “predict”, “project”, “potential”, “seem”. “seek”, “future”, “outlook”, “forecast”, “projection”, “continue”, “ongoing”, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this Report may include, for example, statements about:


•D-Wave's future growth and innovations;
•the increased adoption of quantum computing solutions and expansion of related market opportunities and use cases;
•D-Wave's expectations regarding product development and functionality;
•D-Wave’s financial and business performance, including financial projections and business metrics;
•changes in D-Wave’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans;
•the ability of D-Wave’s products and services to meet customers’ compliance and regulatory needs;
•D-Wave’s ability to attract and retain qualified employees and management;
•developments and projections relating to D-Wave’s products, competitors and industry;
•the impact of the current economic environment due to inflation, increased interest rates, Ukraine/Russia conflict, and any evolutions thereof, on D-Wave’s business and the actions D-Wave may take in response thereto;
•D-Wave’s expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
•D-Wave's expectations about the Term Loan (as defined below) providing it sufficient cash runway;
•the additional expected costs relating to D-Wave becoming a public company;
•D-Wave’s future capital requirements and sources and uses of cash;
•D-Wave’s ability to obtain funding for its operations and future growth; and
•D-Wave’s business, expansion plans and opportunities.

You should not place undue reliance on these forward-looking statements in making an investment decision. These forward-looking statements are based on information available as of the date of this Report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties and are not predictions of actual performance. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

These forward-looking statements are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability regarding future performance, events or circumstances. Many of the factors affecting actual performance, events and circumstances are beyond the control of D-Wave. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements.

Some factors that could cause actual results to differ include:
•anticipated trends, growth rates, and challenges in companies, such as D-Wave, that are engaged in the business of quantum computing and in the markets in which they operate;
•the risk that D-Wave’s securities will not maintain a listing on the New York Stock Exchange (“NYSE”);
3
Table of Contents
•risks related to the uncertainty of the unaudited prospective forecasted financial information;
•risks related to the possibility that D-Wave may not be able to retain a new auditor;
•risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones;
•unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof;
•the performance of D-Wave’s products and services;
•the effects of competition on D-Wave’s business;
•changes in the business of D-Wave, D-Wave’s market, financial, political and legal conditions;
•the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all;
•the risk that D-Wave may never achieve or sustain profitability;
•the risk that D-Wave is unable to secure or protect its intellectual property;
•changes in applicable laws or regulations;
•the effect of the current economic environment due to inflation, increased interest rates, Ukraine/Russia conflict, geopolitical events, natural disasters, wars, terrorist acts or a combination of these factors on D-Wave’s business and the economy in general;
•the ability of D-Wave to execute its business model, including market acceptance of its planned products and services;
•D-Wave’s ability to raise capital, including under the Purchase Agreement (as defined below) with Lincoln Park Capital Fund LLC ("Lincoln Park");
•D-Wave's ability to obtain funds under the Term Loan (as defined below);
•the possibility that D-Wave may be negatively impacted by other economic, business, and/or competitive factors;
•risks stemming from inflation;
•any changes to applicable tax laws, including U.S. tax laws; and
•other risks and uncertainties described in Report, including those referenced under the section titled “Risk Factors.”

In addition, statements that “D-Wave believes” and similar statements reflect D-Wave’s beliefs and opinions on the relevant subject. These statements are based upon information available to D-Wave as of the date of this Report, and while D-Wave believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that such party has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
4
Table of Contents
Part I - Financial Information
Item 1. Financial Statements

D-Wave Quantum Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
June 30, December 31,
(In thousands of U.S. dollars, except share and per share data) 2023 2022
Assets
   Current assets:
     Cash $ 7,514  $ 7,065 
     Trade accounts receivable, net 803  757 
     Inventories 2,325  2,196 
     Prepaid expenses and other current assets 2,200  3,907 
Total current assets $ 12,842  $ 13,925 
Property and equipment, net 1,792  2,294 
Operating lease right-of-use assets 8,716  9,133 
Intangible assets, net 205  244 
Other noncurrent assets 1,354  1,351 
Total assets $ 24,909  $ 26,947 
Liabilities and stockholders' (deficit) equity
   Current liabilities:
     Trade accounts payable 4,106  3,756 
     Accrued expenses and other current liabilities 10,800  8,640 
     Loans payable, current 15,910  1,671 
     Deferred revenue, current 2,827  1,781 
Total current liabilities 33,643  15,848 
Warrant liabilities 3,404  1,892 
Operating lease liabilities, net of current portion 7,162  7,301 
Loans payable, noncurrent 8,473  7,811 
Deferred revenue, noncurrent 120  9 
Total liabilities $ 52,802  $ 32,861 
Commitments and contingencies (Note 11)
Stockholders' (deficit) equity:
Common stock par value $0.0001 per share; 675,000,000 shares authorized at June 30, 2023 and December 31, 2022; 128,028,658 shares and 113,335,530 shares issued and outstanding as of June 30, 2023 and December 31, 2022.
 12  11 
Additional paid-in capital 409,885  381,274 
Accumulated deficit (427,303) (376,797)
Accumulated other comprehensive loss (10,487) (10,402)
     Total stockholders' (deficit) equity $ (27,893) $ (5,914)
Total liabilities and stockholders’ equity $ 24,909  $ 26,947 

The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Table of Contents
D-Wave Quantum Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
For the three months ended June 30, For the six months ended June 30,
(In thousands, except share and per share data) 2023 2022 2023 2022
Revenue $ 1,707  $ 1,371  $ 3,290  $ 3,083 
Cost of revenue 1,002  620  2,164  1,235 
          Total gross profit 705  751  1,126  1,848 
Operating expenses:
   Research and development 9,548  7,456  20,463  14,260 
   General and administrative 9,576  3,959  20,872  7,606 
   Sales and marketing 2,488  1,739  5,388  3,339 
   Total operating expenses 21,612  13,154  46,723  25,205 
          Loss from operations (20,907) (12,403) (45,597) (23,357)
Other income (expense), net:
   Interest expense (781) (1,479) (1,235) (2,262)
   Change in fair value of warrant liabilities (2,150) —  (1,512) — 
  Change in fair value of Term Loan (345) —  (345) — 
   Term Loan debt issuance costs (1,393) —  (1,393) — 
   Other income (expense), net (322) 533  (424) 353 
Total other income (expense), net (4,991) (946) (4,909) (1,909)
   Net loss $ (25,898) $ (13,349) $ (50,506) $ (25,266)
Net loss per share, basic and diluted $ (0.20) $ (0.11) $ (0.40) $ (0.20)
Weighted-average shares * used in computing net loss per share, basic and diluted 127,337,903  125,472,590  125,252,585  125,428,749 
Comprehensive loss:
Net loss $ (25,898) $ (13,349) $ (50,506) $ (25,266)
Foreign currency translation adjustment, net of tax (66) 32  (85) (38)
          Net comprehensive loss $ (25,964) $ (13,317) $ (50,591) $ (25,304)
* Weighted-average shares for the three and six months ended June 30, 2022 have been retroactively restated to give effect to the Merger.

The accompanying notes are an integral part of these condensed consolidated financial statements.
6
Table of Contents
D-Wave Quantum Inc.
Condensed consolidated statements of stockholders’ (deficit) equity
(Unaudited)
Stockholders’ (Deficit) Equity
Non-redeemable convertible preferred stock Common stock Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total stockholders' equity (deficit)
(In thousands, except share data) Shares Amount Shares Amount
Balances at December 31, 2021 137,765,828  $ 189,881  3,166,949  $ 2,610  $ 146,240  $ (325,268) $ (10,443) $ 3,020 
Retroactive application of Merger (15,201,495) —  (349,451) (2,610) 2,610  —  —  — 
Adjusted Balances, beginning of period* 122,564,333  189,881  2,817,498  —  148,850  (325,268) (10,443) 3,020 
Old D-Wave exercise of stock options —  —  155,137  —  141  —  —  141 
Old D-Wave stock-based compensation —  —  —  —  1,600  —  —  1,600 
Foreign currency translation adjustment, net of tax —  —  —  —  —  —  (38) (38)
Net loss —  —  —  —  —  (25,266) —  (25,266)
Balances at June 30, 2022 122,564,333  $ 189,881  2,972,635  $ —  $ 150,591  $ (350,534) $ (10,481) $ (20,543)
* Shares of legacy non-redeemable convertible preferred stock and legacy common stock have been retroactively restated to give effect to the Merger.

The accompanying notes are an integral part of these condensed consolidated financial statements.
7
Table of Contents
D-Wave Quantum Inc.
Condensed consolidated statements of stockholders’ (deficit) equity
(Unaudited)
Stockholders’ Equity
Common stock
(In thousands, except share data) Shares Amount Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total stockholders' deficit
Balances at December 31, 2022 113,335,530  $ 11  $ 381,274  $ (376,797) $ (10,402) $ (5,914)
Exercise of stock options 1,453,474  —  1,208  —  —  1,208 
Issuance of common stock in connection with the Purchase Agreement 13,239,654  1  15,682  —  —  15,683 
Stock-based compensation —  —  11,477  —  —  11,477 
Short swing profit settlement —  —  244  —  —  244 
Foreign currency translation adjustment, net of tax —  —  —  —  (85) (85)
Net loss —  —  —  (50,506) —  (50,506)
Balances at June 30, 2023 128,028,658  $ 12  $ 409,885  $ (427,303) $ (10,487) $ (27,893)

The accompanying notes are an integral part of these condensed consolidated financial statements.

8
Table of Contents
D-Wave Quantum Inc.
Condensed consolidated statements of cash flows
(Unaudited)
Six months ended June 30,
(in thousands) 2023 2022
Cash flows from operating activities:
Net loss $ (50,506) $ (25,266)
Adjustments to reconcile net loss to cash used in by operating activities:
  Depreciation and amortization 601  705 
  Stock-based compensation 11,477  1,600 
  Amortization of operating right of use assets 417  459 
  Non-cash interest expense 1,198  1,679 
  Change in fair value of Warrant liabilities 1,512  — 
  Change in fair value of Term Loan 345  — 
  Debt issuance costs netted from Term Loan proceeds 643  — 
  Other non-cash activities 395  499 
  Change in operating assets and liabilities:
     Trade accounts receivable (40) (266)
     Inventories (81) (301)
     Prepaid expenses and other current assets 1,709  (4,330)
     Trade accounts payable 338  (136)
     Accrued expenses and other current liabilities 2,126  4,578 
     Deferred revenue 1,157  (293)
     Operating lease liabilities, net of current portion (335) (427)
       Net cash used in operating activities $ (29,044) $ (21,499)
Cash flows from investing activities:
  Purchase of property and equipment (59) (175)
  Purchase of software (20) (43)
     Net cash used in investing activities $ (79) $ (218)
Cash flows from financing activities:
  Proceeds from Lincoln Park Purchase Agreement 15,683  — 
  Proceeds from government assistance —  3,178 
  Proceeds from issuance of common stock upon exercise of stock options 1,208  141 
  Proceeds from Term Loan 14,357  19,870 
  Debt payments (1,835) (424)
  Short swing profit settlement 244  — 
     Net cash provided by financing activities $ 29,657  $ 22,765 
Effect of exchange rate changes on cash and cash equivalents (85) (65)
     Net (decrease) increase in cash and cash equivalents 449  983 
Cash and cash equivalents at beginning of period $ 7,065  $ 9,483 
Cash and cash equivalents at end of period $ 7,514  $ 10,466 
Supplemental disclosure of noncash investing and financial activities:
Unpaid deferred costs $ —  $ 3,734 

The accompanying notes are an integral part of these condensed consolidated financial statements.
9
Table of Contents
D-Wave Quantum Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1.    Description of business

D-Wave Quantum Inc. ("D-Wave" or the “Company”) was incorporated under the General Corporation Law of the State of the Delaware on January 24, 2022. The Company was formed for the purpose of effecting a merger between DPCM Capital, Inc. (“DPCM”), D-Wave Systems Inc. (“D-Wave Systems”), and certain other affiliated entities through a series of transactions (the “Merger”) pursuant to the definitive agreement entered into on February 7, 2022 (the “Transaction Agreement”). On August 5, 2022, in conjunction with the Merger, DPCM and D-Wave Systems became wholly-owned subsidiaries of, and are operated by, the Company. Upon the completion of the Merger, the Company succeeded to all of the operations of its predecessor, D-Wave Systems.
D-Wave is a commercial quantum computing company that provides customers with a full suite of professional services and web-based access to its superconducting quantum computer systems and integrated software environment through its cloud service, LeapTM. Historically, the Company has developed its own annealing superconducting quantum computer and associated software, and its current generation quantum system is the AdvantageTM system.
D-Wave has three operating facilities, which it leases, in North America. These facilities are located in Burnaby, British Columbia, Richmond, British Columbia, and Palo Alto, California.
2.    Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
The unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the condensed consolidated balance sheet as of December 31, 2022, has been derived from the audited consolidated financial statements at that date, but certain notes or other information that are normally required by U.S. GAAP have been omitted if they substantially duplicate the disclosures contained in the Company's annual audited consolidated financial statements.
Certain information and footnote disclosure normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission ("SEC"). In the opinion of the Company, the unaudited financial information for the interim periods presented reflects all adjustments, which are normal and recurring, necessary for a fair presentation of the consolidated statement of operations and comprehensive loss, balance sheet, and cash flows. Interim results should not be regarded as indicative of results that may be expected for any other period or the entire year.
The interim condensed consolidated financial statements included herein have been prepared on the same basis as the audited annual consolidated financial statements and reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K as of and for the year ended December 31, 2022 filed with the SEC.
The condensed consolidated statement of operations and comprehensive loss for the three and six month periods ended June 30, 2023 are not necessarily indicative of the results to be anticipated for the entire year ending December 31, 2023 or thereafter. All references to June 30, 2023 and 2022 in the notes to condensed consolidated financial statements are unaudited.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements upon consolidation.
Revision of previously issued financial statements
In connection with the preparation of the Company’s financial statements as of and for the year ended December 31, 2022, the Company’s management identified certain misstatements attributable to the following:
10
Table of Contents
i) an understatement of reported research and development expenses for the three and six months ended June 30, 2022 of $0.4 million and $0.7 million, respectively, with respect to the Company losing the ability to receive Scientific Research and Experimental Development credits subsequently to signing the Transaction Agreement on February 7, 2022; and
ii) an overstatement of non-cash interest expense for the three and six months ended June 30, 2022 of $0.3 million and $0.3 million, respectively, with respect to the Company identifying certain errors in the SIF Loan (as defined below) repayment calculation model.
There was no material impact to net loss, hence there was no impact to the net loss per share, for the three and six months ended June 30, 2022.
Liquidity and going concern
The Company has prepared its condensed consolidated financial statements assuming that it will continue as a going concern. Since its inception, the Company has incurred net losses and negative cash flows from operations. As of June 30, 2023, the Company had an accumulated deficit of $427.3 million. For the three and six months ended June 30, 2023, the Company incurred a net loss of $25.9 million and $50.5 million, respectively. For the three and six months ended June 30, 2022, the Company incurred a net loss of $13.3 million and $25.3 million, respectively. For the six months ended June 30, 2023 and 2022, the Company had net cash outflows from operating activities of $29.0 million and $21.5 million, respectively. As of June 30, 2023, the Company had $7.5 million of cash and working capital (current assets less current liabilities) deficit of $20.8 million. The Company expects to incur additional operating losses and negative cash flows from operating activities as it continues to expand its commercial operations and research and development programs.

On April 13, 2023, (the "Closing Date") the Company entered into the Term Loan and Security Agreement (the "Term Loan"), by and between the Company and PSPIB Unitas Investments II Inc. ("PSPIB" or the "Lender"), a related party to the Company's largest shareholder. As further described in Note 7 - Loans payable, the Term Loan provides for an aggregate principal amount of $50.0 million to be made available to the Company in three tranches, subject to certain terms and conditions as defined in the Term Loan, including a financial covenant that measures the Company's revenue against certain minimum percentages of budgeted revenue per quarter. The first two tranches of the Term Loan, each amounting to $15.0 million in principal, were advanced to D-Wave on April 14, 2023 and July 13, 2023, respectively, with the third tranche of $20.0 million to be made available on October 10, 2023, subject to certain conditions. The Lender agreed to modify certain conditions to the funding of the second tranche of the Term Loan, including delaying the delivery of a board-approved operating budget and plan for the Company’s fiscal years 2023 through 2027 to August 31, 2023; modifying the condition that, prior to the funding of the second tranche,the Company shall have nominated an additional director that is either an employee of PSPIB or an independent director selected from PSPIB nominees to require such appointment at a later time at PSPIB’s option; and modifying notice deadline requirements for the registration or filings of intellectual property. PSPIB has also agreed to waive certain covenants under the Term Loan that the Company did not meet, including the minimum revenue financial covenant for the second fiscal quarter ended June 30, 2023. The third tranche that shall be available to D-Wave as of October 10, 2023, is subject to the closing of a $25.0 million non-dilutive financing on terms reasonably acceptable to the Lender, and the intellectual property valuation report submitted as a condition precedent to the second tranche and the board-approved operating budget for 2023 through 2027 being submitted by August 31, 2023 both remaining satisfactory to the Lender. There can be no assurance that the Company will be able to meet the conditions necessary to draw on the third tranche or will be able to comply with the covenants of the Term Loan, or that PSPIB will agree to waive covenants under the Term Loan in the future.

In conjunction with the Merger, the Company and D-Wave Systems entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park") on June 16, 2022 (the "Purchase Agreement" or the "Lincoln Park Purchase Agreement") which provides D-Wave the sole right, but not the obligation, to direct Lincoln Park to buy specified dollar amounts up to $150 million of D-Wave's common stock, par value $0.0001 per share (the "Common Shares") through October 26, 2025. The Purchase Agreement may provide the Company and D-Wave with additional liquidity to fund the business, subject to the conditions set forth in the agreement, including volume limitations tied to periodic market prices, ownership limitations restricting Lincoln Park from owning more than 9.9% of the then total outstanding Common Shares and a floor price of $1.00 at or below which the Company may not sell to Lincoln Park any Common Shares. When the Company sells shares to Lincoln Park, Lincoln Park may resell all, some, or none of those Common Shares at any time or from time to time in its discretion. For the six months ended June 30, 2023, the Company has received $15.7 million in proceeds through the issuance of 13,239,654 Common Shares to Lincoln Park under the Purchase Agreement. In order for the Company to issue common shares under the Purchase Agreement, the Company's share price must be above the floor price of $1.00 per share. There is no assurance that the floor price will not fall below $1.00 preventing the Company from being able to make sales to Lincoln Park in the future.
11
Table of Contents
To the extent that sufficient capital is not obtained through the cash received in connection with the proceeds of the Term Loan or the issuance of Common Shares under the Purchase Agreement with Lincoln Park, management will be required to obtain additional capital through the issuance of debt and/or equity, or other arrangements. However, there can be no assurance that D-Wave will be able to raise additional capital when needed or under acceptable terms. The issuance of additional equity may dilute existing stockholders and newly issued shares may contain senior rights and preferences compared to the currently outstanding common stock. Any future debt may contain covenants and limit D-Wave’s ability to pay dividends or make other distributions to stockholders. If D-Wave is unable to obtain additional financing, operations will be scaled back or discontinued.
As further described in Note 13 - Subsequent events, subsequent to the three months ended June 30, 2023, D-Wave was advanced $15.0 million under the second tranche of the Term Loan and, following the execution of the third amendment to the Term Loan and a registration statement relating to the resale of up to 35 million Common Shares under the Lincoln Park Purchase Agreement being declared effective, issued 16,590,877 Common Shares in connection with the Lincoln Park Purchase Agreement for total proceeds of $34.2 million. Notwithstanding these subsequent events, in connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Codification (“ASC”) Topic 205-40, “Basis of Presentation—Going Concern”, management has determined that the Company's liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these financial statements. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Such adjustments could be material.

Use of estimates
The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes as of the date of the condensed consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience.
The Company’s accounting estimates and assumptions may change over time in response to risks and uncertainties, including uncertainty in the current economic environment due to inflation, increased interest rates, Ukraine/Russia conflict, and any evolutions thereof. The change could be material in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstances that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.
Debt
The Company determined that it is eligible for the fair value option election in connection with the Term Loan. The Term Loan meets the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair value option under ASC 825-10-15-4 and does not meet the definition of any of the financial instruments found within ASC 825-10-15-5 that are not eligible for the fair value option. At the date of issuance, the fair value of the Term Loan is derived from the instrument’s implied discount rate at inception.
Changes in the fair value of the Term Loan, other than changes associated with the Company's own credit risk, are recorded as gains or losses in the Company’s condensed consolidated statements of operations and comprehensive loss in each reporting period. Changes in fair value attributable to the Company's own credit risk are recorded in other comprehensive income or loss in the Company's condensed consolidated statements of operations and comprehensive loss in each reporting period; there have been no such changes for the three and six months ended June 30, 2023. Under the fair value option, debt issuance costs are recorded in other expense in the Company’s condensed consolidated statements of operations and comprehensive loss.
The Term Loan is subject to certain repayment and prepayment provisions which the Company has considered in their valuation analysis. The valuation analysis performed as of the issuance date on April 13, 2023 and June 30, 2023 did not consider any amendments to the Term Loan that occurred subsequent to June 30, 2023 (see to Note 13 - Subsequent events). A Monte Carlo simulation model was utilized to forecast the probability of the issuance of Common Shares under the Purchase Agreement to determine the estimated proceeds to be paid to the Lender along with a mandatory prepayment premium of 10%. Additionally, the Company estimated the probability for an event of default in the valuation analysis which would result in a mandatory prepayment of the outstanding principal and accrued and unpaid interest.
12
Table of Contents
A binomial lattice model was utilized to determine the impact on the valuation of optional prepayments, in the event a mandatory prepayment does not occur. The Company assessed the fair value of the Term Loan at issuance date and as of June 30, 2023 resulting in unrealized losses of $0.3 million for the three and six months ended June 30, 2023, respectively.
Fair value of financial instruments
Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
⮚Level 1—Quoted prices in active markets for identical assets or liabilities.
⮚Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
⮚Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.
The carrying amounts reflected in the condensed consolidated balance sheets for cash , trade accounts receivable, net, trade accounts payable and accrued expenses approximate their fair values (Level 1).
The Company carries its marketable investments at cost, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments by the same issuer, as they represent investments in privately held companies for which there are no quoted market prices. As of June 30, 2023 and December 31, 2022, the carrying values of the Company's marketable investments were $1.2 million, respectively, and were reported in other noncurrent assets in the consolidated balance sheets.
The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis as of June 30, 2023 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value (in thousands):

Description Level June 30, 2023
Liabilities:
Warrant Liabilities – Public Warrants 1 $ 1,884 
Warrant Liabilities – Private Placement Warrants 2 $ 1,520 
Term Loan 3 $ 15,700 

The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the condensed consolidated statements of operations.
For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrants was used as the fair value of the Warrants as of each relevant date. The subsequent measurements of the Public Warrants after the detachment of the Public Warrants from the Units are classified as Level 1 fair value measurements due to the use of an observable market quote in an active market. The subsequent measurements of the Private Warrants after the detachment of the Public Warrants from the Units are classified as Level 2 fair value measurements due to the use of an observable market quote for the Public Warrants, which are considered to be a similar asset in an active market.
13
Table of Contents
As of June 30, 2023, the liabilities for the Warrants were calculated by multiplying the quoted market price per DPCM Public Warrant of $0.19 by the17,916,609 Warrants outstanding (see Note 8).
The Company elected the fair value option for its Term Loan. This liability is deemed to be a Level 3 valuation. The Company adjusts the Term Loan to fair value through the change in fair value of Term Loan in the accompanying condensed consolidated statements of operations and comprehensive loss.
Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs

Government assistance
The Company receives various forms of government assistance including (i) government grants (ii) investment credits, and (iii) government loans, for research and development initiatives from Canadian government agencies.
During the three and six months ended June 30, 2022, the Company recorded Scientific Research and Experimental Development (“SR&ED") investment tax credits of $0.4 million and $0.8 million, respectively, as an offset to its research and development expenses in its condensed consolidated statements of operations and comprehensive loss. Upon entering into the Transaction Agreement on February 7, 2022, the Company is no longer a Canadian Controlled Private Corporation. As a result, beginning February 7, 2022, SR&ED investment tax credits can be applied to reduce income taxes payable to the Canadian government and any such investment tax credits that are not realized will be reflected as investment tax credit carryforwards. During the three and six months ended June 30, 2023, the Company did not record any SR&ED investment tax credits.
Recent accounting pronouncements issued and adopted
No recently issued accounting pronouncements that the Company has adopted have had a material effect on the Company's results of operations, cash flows or financial condition.
Recent accounting pronouncements not yet adopted
No other recently issued accounting pronouncements or effective during 2023 had, or are expected to have, a material impact on the Company’s results of operations, cash flows or financial condition.
3. Merger
On August 5, 2022, the Company completed the Merger. Upon the closing of the Merger, the following occurred:
•Each non-redeeming share of DPCM Class A common stock was converted into the right to receive 1.4541326 Common Shares (the “Exchange Ratio”), such that 902,213 shares of DPCM Class A common stock that were not redeemed were exchanged for 1,311,937 Common Shares;
•All outstanding warrants of DPCM were converted into the right to receive Warrants. Each such Warrant is exercisable for 1.4541326 Common Shares, at any time commencing on September 4, 2022, the date that is 30 days after the completion of the Merger. The number of Common Shares received upon the exercise of Warrants will be rounded down to the nearest whole number of Common Shares;
•3,015,575 shares of DPCM Class B common stock held by Sponsor and DPCM’s officers, directors and other special advisors were converted into Common Shares on a one-for-one basis; and
•Pursuant to an arrangement effected under Part 9, Division 5 of the Business Corporations Act (British Columbia) (the “Arrangement”) all holders of outstanding non-redeemable convertible preferred shares of D-Wave Systems received equity interests in D-Wave in exchange for their equity interests in D-Wave Systems. The aggregate consideration paid to former shareholders of D-Wave Systems in connection with the Merger was approximately 99,736,752 Common Shares and Exchangeable Shares (as defined below) (excluding options of D-Wave Systems and warrants of D-Wave Systems).
“Exchangeable Shares” refers to shares in the capital of D-Wave Quantum Technologies Inc., or ExchangeCo, an indirect Canadian subsidiary of D-Wave. The Exchangeable Shares are exchangeable from time to time, at the holder’s election, for Common Shares on a one-for-one basis.
14
Table of Contents
In connection with the Merger and concurrently with the execution of the Transaction Agreement, on February 7, 2022, DPCM and the Company entered into separate subscription agreements with a number of investors (each a "PIPE Investor"), pursuant to which the PIPE Investors agreed to purchase, and the Company agreed to sell to the PIPE Investors, a number of Common Shares (the “PIPE Shares”) equal to the aggregate purchase price for all Common Shares subscribed for by each PIPE Investor, divided by $10.00 and multiplied by the Exchange Ratio for an aggregate purchase price of $40.0 million (the “PIPE Investment”), such that the PIPE Investors purchased 5,816,528 PIPE Shares in the aggregate. The PIPE Investment closed simultaneously with the consummation of the Merger.
On August 2, 2022, the DPCM shareholders voted to approve the Merger. Management determined that once this vote had occurred, it was probable that D-Wave Quantum Inc. would be required to pay Lincoln Park the Commitment Fee associated with the Purchase Agreement. As such, on August 2, 2022, D-Wave Quantum Inc. incurred a $2.6 million liability payable to Lincoln Park, which was the amount of cash contractually required to settle the Commitment Fee. Other than the Commitment Fee liability, D-Wave Quantum, Inc. had no other assets, liabilities, or operations prior to the closing of the Merger on August 5, 2022.
The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, DPCM was treated as the "acquired" company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of DPCM, accompanied by a recapitalization. The net assets of DPCM were stated at historical cost, with no goodwill or other intangible assets recorded.
4.    Revenue from contracts with customers
Disaggregation of revenue
The following table depicts the disaggregation of revenue by type of products or services and timing of transfer of products or services (in thousands):

Three months ended June 30,
2023 2022
Type of products or services
QCaaS $ 1,032  $ 1,176 
Professional services 655  156 
Other revenue 20  39 
Total revenue, net $ 1,707  $ 1,371 
Timing of revenue recognition
Revenue recognized over the time $ 1,665  $ 1,296 
Revenue recognized at a point in time 42  75 
Total revenue, net $ 1,707  $ 1,371 
Six months ended June 30,
2023 2022
Type of products or services
QCaaS $ 2,201  $ 2,560 
Professional services 1,061  464 
Other revenue 28  59 
Total revenue, net $ 3,290  $ 3,083 
Timing of revenue recognition
Revenue recognized over the time $ 3,207  $ 2,957 
Revenue recognized at a point in time 83  126 
Total revenue, net $ 3,290  $ 3,083 
Other revenue includes training and printed circuit board sales.
The following table presents a summary of revenue by geography for the three and six months ended June 30, 2023 and 2022 (in thousands):

15
Table of Contents
Three months ended June 30,
2023 2022
United States $ 485  $ 655 
Japan 263  282 
Germany 284  257 
Switzerland 274  — 
United Kingdom 170  — 
Other 231  177 
Total revenue $ 1,707  $ 1,371 

Six Months Ended June 30,
2023 2022
United States $ 731  $ 1,439 
Japan 621  709 
Germany 578  520 
Switzerland 375  — 
United Kingdom 401  — 
Other 584  415 
Total revenue $ 3,290  $ 3,083 
"Other" includes the rest of Europe, the Middle East, Africa, Asia, Canada and Australia where the revenue from a single country is not greater than 10% of total consolidated revenue. The Company has not had any sales in China, Russia or Ukraine.
Significant customers
The Company had significant customers during the three and six months ended June 30, 2023 and 2022. A significant customer is defined as one that comprises up to ten percent or more of total revenues in a particular year or ten percent of outstanding accounts receivable balance as of the year end.
The tables below present the significant customers on a percentage of total revenue basis for the three and six months ended June 30, 2023 and 2022.

Three months ended June 30,
2023 2022
Customer A 16  % 17  %
Customer B 14  % 14  %
Customer C 9  % 11  %
Six Months Ended June 30,
2023 2022
Customer A 14  % 15  %
Customer B 11  % 14  %
Customer C 10  % 10  %
As of June 30, 2023 and December 31, 2022, there were four and two significant customers that comprised ten percent or more of outstanding accounts receivable balances, respectively.
All revenues derived from major customers above are located in the United States, Germany and other European countries during the three and six month period ended June 30, 2023 and the United States and Germany during the three and six month period ended June 30, 2022.
16
Table of Contents
Contract balances
The following table provides information about account receivable, contract assets and liabilities as of June 30, 2023 and December 31, 2022 (in thousands):
June 30, December 31,
2023 2022
Contract assets:
Trade account receivable $ 803  $ 757 
Unbilled receivables, included in 'Prepaid expenses and other current assets' 69  58 
   Total contract assets $ 872  $ 815 
Contract liabilities:
Deferred revenue, current 2,827  1,781 
Deferred revenue, noncurrent 120  9 
Customer deposit, included in 'Accrued expenses and other current liabilities' 45  45 
Total contract liabilities $ 2,992  $ 1,835 
Changes in deferred revenue from contracts with customers were as follows (in thousands):
June 30,
2023
Balance at beginning of period $ 1,790 
Deferral of revenue 3,227 
Recognition of deferred revenue (2,070)
Balance at end of period $ 2,947 
Remaining performance obligations
A significant number of the Company’s product and service sales are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less.
As of June 30, 2023, the aggregate amount of remaining performance obligations that were unsatisfied or partially unsatisfied related to customer contracts was $2.9 million. This amount included deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 96% is expected to be recognized to revenue in the next 12 months.
As of December 31, 2022, the aggregate amount of remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied was $1.8 million which included deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 99% was expected to be recognized to revenue in the next 12 months.
17
Table of Contents
5.    Balance sheet details
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
June 30, December 31,
2023 2022
Accrued expenses:
  Accrued transaction costs $ —  $ 2,459 
Accrued professional services 3,873  1,858 
Accrued compensation and related benefits 3,012  1,641 
Other accruals 1,172  233 
Other current liabilities:
Other payroll expenses $ 1,025  $ 451 
Customer deposit 45  45 
Current portion of operating lease liabilities 1,463  1,533 
    Promissory note, related party (Refer to Note 9 - Promissory note, related party) 210  420 
Total accrued expenses and other current liabilities $ 10,800  $ 8,640 
Prepaid expenses and other current assets consisted of the following (in thousands):
June 30, December 31,
2023 2022
Prepaid expenses:
  Prepaid services $ 358  $ 391 
  Prepaid software 426  559 
  Prepaid rent 133  96 
  Prepaid commissions 206  268 
  Prepaid insurance 656  697 
  Other 384  89 
Other current assets:
Directors and Officers insurance $ —  $ 1,449 
Unbilled receivables —  58 
Security deposits 37  36 
Receivable research incentives —  264 
Total prepaid expenses and other current assets $ 2,200  $ 3,907 
6.    Property and equipment, net
Property and equipment, net consisted of the following (in thousands):
June 30, December 31,
2023 2022
Quantum computer systems $ 13,712  $ 13,714 
Lab equipment 6,687  6,666 
Computer equipment 3,573  3,545 
Leasehold improvements 1,075  1,075 
Furniture and fixtures 328  319 
Construction-in-progress 71  86 
Total property and equipment 25,446  25,405 
Less: Accumulated depreciation (23,654) (23,111)
Property and equipment, net $ 1,792  $ 2,294 
18
Table of Contents
Depreciation expense for the three month period ended June 30, 2023 and 2022 was $0.2 million and $0.3 million, respectively. Depreciation expense for the six month period ended June 30, 2023 and 2022 was $0.5 million and $0.7 million, respectively. The Company has not acquired any property and equipment under capital leases.
As of June 30, 2023 and December 31, 2022, substantially all of the Company’s long-lived assets, consisting of property and plant, net, and operating lease right-of-use assets, amounting to $10.5 million and $11.4 million, respectively, are located in North America, principally in Canada.
7.    Loans payable
As of June 30, 2023 and December 31, 2022 loans payable consisted of the refundable government loans. The following table shows the component of loans payable (in thousands):
Interest Rate June 30, December 31,
2023 2022
SIF Loan (1)
 Interest free $ 8,234  $ 7,293 
TPC Loan, due 2025 Interest free $ 239  $ 518 
Total loans payable, noncurrent $ 8,473  $ 7,811 
Loans payable, current
Term Loan (1)
 11.00% $ 15,700  $ — 
TPC Loan, due 2024 Interest free $ 210  $ 206 
Financing of Directors and Officers Insurance, due 2023 4.24% $ —  $ 1,449 
Other loans payable, current, due 2023 Interest free $ —  $ 16 
Total loans payable, current $ 15,910  $ 1,671 
(1) Refer below for additional information on the repayment period.

SIF Loan
On November 20, 2020, the Company entered into an agreement (the "SIF Loan") with the Strategic Innovation Fund ("SIF"), whereby SIF agreed to make a repayable contribution to the Company of up to C$40.0 million (the "Contribution”). Funds from the SIF Loan are to be used for projects involving the adaption of research findings for commercial applications that have the potential for market disruption; development of current product and services through the implementation of new or incremental technology that will enhance the Company’s competitive capability; and development of process improvements which reduce the environmental footprint of current production through the use of new or improved technologies.
The annual repayment of the Contribution is calculated based upon a formula using the Company’s fiscal year revenue multiplied by a repayment rate. The contractual repayment period is 15 years and commences in the first year in which the Company reports annual revenue of $70.0 million (the “Benchmark Year”). In each of those years, an annual repayment amount is due. Each annual repayment must be paid by April 30 of the year following the year for which the annual repayment due will be calculated. If the Benchmark Year is not achieved within 14 years following the fiscal year in which the project is completed, the SIF Loan is forgiven. The SIF Loan is initially recorded at fair value, and subsequently at amortized cost. As the Contribution is interest free, the difference between the carrying value and initial fair value is recorded as government assistance on the consolidated statement of operations and comprehensive loss.
The initial fair value of the SIF Loan is determined by using a discounted cash flow analysis for the loan, which requires a number of assumptions. The significant assumptions used in determining the discounted cash flows include estimating the amount and timing of future revenue for the Company and the appropriate discount rate. In determining the appropriate discount rates, the Company considered the weighted average cost of capital for the Company, risk adjusted based on the development risks of the Company’s product. Management used a discount rate of 26% to discount the SIF Loan. Should projected revenue not be achieved as predicted, the adjustment to the fair value of the SIF Loan could be material. At June 30, 2023, the carrying value of the loan approximates its fair value. The nominal amount of the SIF Loan is $27.2 million (C$36.0 million) as of June 30, 2023. For the six months ended June 30, 2023, the Company recognized $0.8 million in interest expense and $0.2 million in foreign currency losses related to the SIF Loan.
Repayments of the SIF contributions could also be triggered upon default of the agreement, or termination of the agreement, or upon a change of control that has not been approved by the Canadian government. The Canadian government approved the transaction with DPCM conditionally on May 9, 2022, with all conditions being satisfied on the closing date of the Merger.
19
Table of Contents
Term Loan
On April 13, 2023, the Company entered into the Term Loan with PSPIB. Under the Term Loan, term loans in aggregate principal amount of $50.0 million are to be made available to the Company in three tranches, subject to certain terms and conditions.
The Term Loan matures on March 31, 2027, is secured by a first-priority security interest in substantially all of the Company's assets and contains certain operational and financial covenants, including a financial covenant that measures the Company's revenue against certain minimum percentages of budgeted revenue per quarter. The Term Loan is subject to a 2% drawdown fee and requires that any proceeds from the issuance of Common Shares under the Purchase Agreement be applied towards the repayment of advances under the Term Loan. Such repayments are subject to a premium payment equal to 10.0% of the amount then prepaid to the Lender, in addition to the regular prepayment premium applicable on that date, except as modified by the amendment to the Term Loan as discussed in Note 13 – Subsequent events. The Term Loan is subject to a prepayment premium due to the Lender equal to 3% of the amount prepaid/repaid within the first year of the Closing Date, 2% in the second year, 1% in the third year and no prepayment premium thereafter. At the Company's discretion, the Term Loan bears interest on a monthly basis at either (i) 10.0% payable in cash, or (ii) 11.0% payable in kind ('PIK'), with the latter added to the principal value of the Term Loan. For the three and six month ended the Company recognized $0.4 million in PIK interest expense related to the Term Loan.

Prior to PSPIB's advance of the first tranche, the Company satisfied several closing conditions including the provision of a cash flow forecast and the board of directors' retention of an advisor. The first tranche of the Term Loan, in an aggregate principal amount of $15.0 million, was advanced to D-Wave on April 14, 2023, with the second and third tranches, of $15.0 million and $20.0 million to be made available to the Company subject to certain conditions. For the three and six months ended June 30, 2023, the Company has recorded debt issuance cost of $1.4 million as other expense in its condensed consolidated statements of operations and comprehensive loss. PSPIB has agreed to waive certain covenants under the Term Loan that the Company did not meet, including the minimum revenue financial covenant for the quarter ended June 30, 2023. As a result of not meeting the minimum revenue covenant, as of June 30, 2023 the Company assessed its ability to meet such covenant over the next 12 months in accordance with ASC Topic 470, "Debt" and determined that the Term Loan may be callable over this period. Therefore the Term Loan was classified as a current liability on the Company's consolidated balance sheets as of June 30, 2023. There can be no assurance that PSPIB will agree to waive the minimum revenue or other covenants under the Term Loan in the future.

As discussed in Note 13 - Subsequent events, on July 13, 2023, the Company received the second tranche gross proceeds of $15.0 million under the Term Loan. The third tranche, that shall be available as of October 10, 2023, is subject to the Company closing a $25.0 million non-dilutive financing on terms reasonably acceptable to the Lender, and the intellectual property valuation report submitted as a condition precedent to the second tranche and board-approved operating budget for 2023 through 2027 being submitted by August 31, 2023 both remaining satisfactory to the Lender. There can be no assurance that the Company will be able to meet the conditions necessary to draw on the third tranche.
8.    Warrant liabilities
In conjunction with the Merger, the Company assumed 10,000,000 DPCM public warrants and 8,000,000 DPCM private warrants. During the six months ended June 30, 2023, no DPCM public or private warrants were exercised.
As of June 30, 2023, the Company has 17,916,609 Warrants outstanding. As part of the Merger, as described in Note 3 - Merger, each DPCM Public Warrant and Private Warrant that was issued and outstanding immediately prior to the Merger was automatically and irrevocably converted into one D-Wave Quantum warrant. The Warrants are subject to the terms and conditions of the warrant agreement entered into between DPCM, Continental Stock Transfer & Trust Company and the Company (the “Warrant Agreement Amendment” as specified in the Transaction Agreement).
Each such Warrant will be exercisable at an exercise price of $11.50 for 1.4541326 Common Shares, or an approximate exercise price per Common Share of $7.91, subject to adjustments. The Warrants may be exercised for a whole number of shares of the Company. No fractional shares will be issued upon exercise of the Warrants. The Warrants will expire on August 5, 2027, or earlier upon redemption or liquidation.
The Private Warrants are identical to the Public Warrants except that the Private Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees.
20
Table of Contents
If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
The Company may redeem the Public Warrants:
    • in whole and not in part;
    • at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value of the Common Share;
    • if, and only if, the last reported sales price of the shares of the Common Shares for any twenty (20) trading days within the thirty (30) trading-day period ending on the third trading day prior to the date on which a notice of redemption is given equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalization and the like) (the "Reference Value");
    • if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalization and the like), the Private Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above; and
    • if, and only if, there is an effective registration statement covering the issuance of the Common Shares issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day period after written notice of redemption is given, or an exemption from registration is available.
If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the Warrant Agreement Amendment. The exercise price and number of the Common Shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of the Common Shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.
For details of the D-Wave Systems legacy warrants, classified as equity, refer to Note 11 - Commitments and contingencies.

9.    Related party
Promissory notes
In 2022, DPCM and one of its affiliates entered into two unsecured promissory notes of up to $1.0 million each with the Sponsor (the "DPCM Notes"). The purpose of the DPCM Notes was to provide DPCM with additional working capital. All amounts drawn on the DPCM Notes were provided directly to DPCM. The DPCM Notes are not convertible and bear no interest. The principal balance of the DPCM Notes was originally due and payable upon the earlier of the date on which DPCM consummates its initial business combination, or the date that the winding up of DPCM is effective. A total of $0.4 million has been drawn on the DPCM Notes, of which $0.2 million remains outstanding as of June 30, 2023.
In connection with the Merger, the DPCM Notes were assumed by the Company and were amended and restated effective December 31, 2022. The amended and restated notes have identical terms as the DPCM Notes except that the Company must pay the principal balance in equal installments on December 31, 2022, March 31, 2023, and June 30, 2023.
In February 2023, these DPCM Notes were further amended and restated such that the Company must pay the principal balance in equal installments, the first of which was paid on April 30, 2023, and the remaining to be paid on June 30, 2023, August 31, 2023 and October 31, 2023.
The execution of the amended and restated DPCM Notes are related party transactions as these notes are payable to affiliates of the Company.
Short swing profit settlement
For the six months ended June 30, 2023, the Company recorded approximately $0.2 million related to the short swing profit settlement remitted by a shareholder of the Company under Section 16(b) of the Securities Exchange Act of 1934, as amended. The Company recognized the proceeds as an increase to additional paid-in-capital in the condensed consolidated balance sheets as of June 30, 2023, and in the condensed consolidated statements of stockholder's (deficit) equity, as well as in cash provided by financial activities in the condensed consolidated statement of cash flows, for the six months ended June 30, 2023.
21
Table of Contents
10.    Stock-based compensation
For the six months ended June 30, 2023 and 2022, stock-based compensation is associated with stock options, restricted stock units ("RSUs"), and the Company's Employee Stock Purchase Plan ("ESPP").
Common stock option activity
The following table summarizes the Company’s stock option activity during the periods presented (in thousands except share and per share data):
Number of options outstanding Weighted  average  exercise  price  ($) Weighted average remaining contractual term (years) Aggregate intrinsic value ($)
Balance as of December 31, 2022 15,387,546 $ 1.76  7.12 $ 8,763 
Granted — —  —  — 
Exercised (1,486,404) 0.81  —  70 
Forfeited (924,993) 4.15  —  — 
Expired (261,476) 1.84  —  — 
Balance as of June 30, 2023 12,714,673 $ 1.70  6.78 $ 14,344 
Options exercisable as of June 30, 2023 10,478,450 $ 1.19  6.45 $ 12,545 
Options unvested as of June 30, 2023 2,229,789 $ 4.09  8.35 $ 1,791 
The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the estimated fair value of the Common Shares for those stock options that had exercise prices lower than the fair value of the Common Shares.
As of June 30, 2023, total unrecognized compensation cost related to unvested stock option grants was approximately $6.7 million. This amount is expected to be recognized over a weighted average period of approximately 0.77 years.
The total fair values of the stock options vested during the six months ended June 30, 2023 and 2022 was $2.4 million and $1.7 million respectively.
Restricted stock unit awards
In accordance with D-Wave's 2022 Equity Incentive Plan ("the 2022 Plan") RSUs granted to employees during the six months ended June 30, 2023 are subject to a service condition and will vest 25% on the first anniversary of the grant date, and then 6.25% each quarter subsequent to the first anniversary for twelve quarters. RSUs granted to members of the Board of Directors during the six months ended June 30, 2023 are subject to a service condition, and will be fully vested on the date of the Company's 2024 annual shareholder meeting.
The following table summarizes the RSU activity and related information under the 2022 Plan:
Number of Outstanding Weighted average Grant Date Fair Value ($)
Unvested as of December 31, 2022 8,143,304  $ 5.69 
Granted 4,423,933  0.89 
Forfeited (1,296,912) 4.75 
Vested (167,605) 4.02 
Unvested as of June 30, 2023 11,102,720  3.93 
Expected to vest as of June 30, 2023 10,503,954  $ 3.97 
For the six months ended June 30, 2023, the weighted-average grant-date fair value of RSUs granted was $0.89. There were 167,605 RSUs vested during the six months ended June 30, 2023. As of June 30, 2023, the unrecognized stock-based compensation cost related to the RSUs was $30.4 million, which is expected to be recognized over a weighted-average period of 2.63 years.
22
Table of Contents
Employment Stock Purchase Plan
In August 2022, the Company established the 2022 ESPP. The maximum number of shares of common stock that may be issued under the ESPP was initially 8,036,455. The number of shares reserved and available for issuance under the ESPP automatically increases each January 1, beginning on January 1, 2023 and each January 1 thereafter ending on January 1, 2032, by the lesser of (i) 1,607,291 shares of common stock, or (ii) 1.0% of the aggregate number of (i) shares of common stock outstanding and (ii) securities convertible into or exercisable for shares of common stock (whether vested or unvested) outstanding on December 31 of the preceding calendar year. As of June 30, 2023, the number of shares of common stock that may be issued under the ESPP is 8,036,455. As of June 30, 2023, 226,453 shares of common stock have been issued under the ESPP.
During the three and six months ended June 30, 2023, the Company recorded stock-based compensation expense related to the ESPP of $0.1 million and $0.2 million, respectively, primarily classified as operating expenses within the consolidated statements of operations and comprehensive loss.
Stock-based compensation expense
The following table summarizes the stock-based compensation expense classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

Three months ended June 30,
2023 2022
Cost of revenue $ 232  $ 34 
Research and development 1,663  84 
General and administrative 2,642  641 
Sales and marketing 184  58 
Total stock-based compensation $ 4,721  $ 817 
Six months ended June 30,
2023 2022
Cost of revenue $ 610  $ 66 
Research and development 4,424  144 
General and administrative 5,935  1,270 
Sales and marketing 508  120 
Total stock-based compensation $ 11,477  $ 1,600 

11.    Commitments and contingencies
D-Wave Systems Warrant Transaction Agreements
In November 2020, contemporaneously with a revenue arrangement, D-Wave Systems entered into a contract, pursuant to which D-Wave Systems agreed to cancel a previously issued warrant with a customer and replace it with a warrant to acquire up to 3,247,637 shares of its Class A Preferred Shares (the “Warrant Preferred Shares”), subject to certain vesting requirements. As the warrant was issued in connection with an existing commercial agreement with a customer, the value of the warrant was determined to be consideration payable to the customer and consequently will be treated as a reduction to revenue recognized under the corresponding revenue arrangement. Approximately 40% of the previously issued warrants had vested and became immediately exercisable on August 13, 2020. The agreement was terminated November 28, 2022 and as a result, any unvested Warrant Preferred Shares will not vest and become exercisable. The vested warrant will remain exercisable until November 29, 2026.

Leases
The Company primarily enters into leases for office space that are classified as operating leases. During each of the six months ended June 30, 2023,and 2022, total operating lease costs were $0.4 million.
23
Table of Contents
Litigation
From time to time, the Company may become involved in various legal proceedings in the ordinary course of its business and may be subject to third-party infringement claims.
In the normal course of business, the Company may agree to indemnify third parties with whom it enters into contractual relationships, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed, under certain conditions, to hold these third parties harmless against specified losses, such as those arising from a breach of representations or covenants, other third-party claims that the Company’s products when used for their intended purposes infringe the intellectual property rights of such other third parties, or other claims made against certain parties. It is not possible to determine the maximum potential amount of liability under these indemnification obligations due to the Company’s limited history of prior indemnification claims and the unique facts and circumstances that are likely to be involved in each particular claim.
As of June 30, 2023 and 2022, the Company was not subject to any material litigation or pending litigation claims.
12.    Net loss per share

As a result of the Merger (see Note 3), for the three months ended June 30, 2022, the Company has retroactively adjusted the weighted average shares outstanding prior to August 5, 2022 to give effect to the Conversion Ratio used to determine the number of Common Shares into which they were converted.
The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2023 and 2022 (in thousands, except share and per share data):
For the three months ended June 30,
2023 2022
Numerator:
Net loss attributable to common stockholders - basic and diluted $ (25,898) $ (13,349)
Denominator:
Weighted-average common stock outstanding 127,337,903  125,472,590 
Net loss per share attributable to common stockholders - basic and diluted $ (0.20) $ (0.11)

For the six months ended June 30,
2023 2022
Numerator:
Net loss attributable to common stockholders - basic and diluted $ (50,506) $ (25,266)
Denominator:
Weighted-average common stock outstanding 125,252,585  125,428,749 
Net loss per share attributable to common stockholders - basic and diluted $ (0.40) $ (0.20)
As of June 30, 2023 and 2022, the Company’s potentially dilutive securities were stock options, the Warrant Shares, and the Public Warrants and Private Warrants.
Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive.
Potentially dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:
For the six months ended June 30,
2023 2022
Public Warrants as converted to Common Shares (Note 8) 14,420,065  — 
Private Warrants as converted to Common Shares (Note 8) 11,633,061  — 
D-Wave Systems Warrant Shares as converted to Common Shares (Note 11) 2,889,282  2,889,282 
Options to purchase common stock as converted to Common Shares 11,311,698  13,621,251 
Total 40,254,106  16,510,533 
24
Table of Contents
13.    Subsequent events
The Company has evaluated all events occurring through August 10, 2023, the date on which the condensed consolidated financial statements were issued, and during which time, nothing has occurred outside the normal course of business operations that would require disclosure except the following:

•On July 13, 2023, the Company received the second tranche gross proceeds of $15.0 million under the Term Loan between the Company and PSPIB. Under the Term Loan, term loans in the aggregate principal amount of $50.0 million are to be made available to the Company in three tranches, subject to certain terms and conditions (refer to Note 7 - Term Loan). The Lender agreed to modify certain conditions to the funding of the second tranche of the Term Loan, including (i) delaying the delivery of a board-approved operating budget and plan for the Company’s fiscal years 2023 through 2027 to August 31, 2023; (ii) the Company shall have nominated an additional director that is either an employee of PSPIB or an independent director selected from PSPIB nominees prior to the funding of the second tranche, instead requiring such appointment at a later time at PSPIB’s option; and (iii) delaying notice requirements for the registration or filings of intellectual property. PSPIB has also agreed to waive certain covenants under the Term Loan that the Company did not meet, including certain revenue milestones for the second fiscal quarter ended June 30, 2023. There can be no assurance that the Company will be able to meet the conditions necessary to draw on the third tranche, will be able to comply with the covenants of the Term Loan, or that PSPIB will agree to waive covenants under the Term Loan in the future.
•On July 13, 2023, a registration statement relating to the resale of up to 35,000,000 Common Shares under the Lincoln Park Purchase Agreement became effective.
•On July 20, 2023 the Term Loan was amended such that the Company may issue up to $50.0 million under the Lincoln Park Purchase Agreement through October 18, 2023 without the requirement to pay down the Term Loan to the extent that proceeds under the Purchase Agreement are received prior to October 18, 2023. As amended, the Term Loan requires that any proceeds from the issuance of Common Shares under the Purchase Agreement in excess of $50.0 million shall be applied towards the repayment of advances under the Term Loan in addition to a premium payment equal to 10% of the amount then prepaid to the Lender.
•From July 24, 2023 to August 7, 2023, the Company issued 16,590,877 Common Shares in connection with the Lincoln Park Purchase Agreement for total proceeds of $34.2 million.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
25
Table of Contents
D-WAVE QUANTUM INC.'S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion is intended to assist you in understanding our present business and the results of operations together with our present financial condition. This section should be read in conjunction with our unaudited condensed consolidated financial statements and the accompanying notes contained in Part I, Item I of this Report, as well as our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on April 18, 2023. In this section, unless otherwise specified, the terms “we”, “our”, “us”, D-Wave" or the "Company" refer to D-Wave Quantum Inc. and its subsidiaries following the closing of the Merger on August 5, 2022 (the "Closing") while "D-Wave Systems" refers to D-Wave Systems Inc. prior to the Closing. All other capitalized terms have the meanings ascribed thereto elsewhere in this Report. All dollar amounts are expressed in thousands of United States dollars (“$”), unless otherwise indicated.
Overview
We are a commercial quantum computing company that provides customers with a full suite of professional services and web-based access to our superconducting quantum computer systems and integrated software environment through our cloud service, LeapTM. Historically, we have developed our own annealing superconducting quantum computer and associated software, and our current generation quantum system is the AdvantageTM system. We are a leader in the development and delivery of quantum computing systems, software and services, and we are the world’s first commercial supplier of quantum computers. Our business model is focused primarily on generating revenue from providing customers access to our quantum computing systems via the cloud in the form of Quantum Computing as a Service ("QCaaS") products, and from providing professional services wherein we assist our customers in identifying and implementing quantum computing applications.
During the three months ended June 30, 2023 and 2022, we recognized revenue from our cloud and professional services of $1.7 million and $1.4 million, respectively. We have incurred significant operating losses since inception. For the six months ended June 30, 2023 and 2022, our net loss was $50.5 million and $25.3 million, respectively. We expect to continue to incur significant losses for the foreseeable future as we continue to invest in various research and development programs and go-to-market initiatives. As of June 30, 2023, we had an accumulated deficit of $427.3 million.
Recent developments
On June 16, 2022, we entered into the Purchase Agreement with Lincoln Park pursuant to which Lincoln Park has agreed to purchase up to $150.0 million of Common Shares through the Purchase Agreement (subject to certain limitations contained in the Purchase Agreement) from time to time over a 36-month period, to assist us in meeting our capital requirements. However, we may not sell any Common Shares to Lincoln Park unless the price of our Common Shares exceeds the Floor Price of $1.00.
The resale of our Common Shares by Lincoln Park related to the Purchase Agreement was registered under the Securities Act of 1933, as amended (the "Securities Act") pursuant to a registration statement filed with the SEC, declared effective by the Securities and Exchange Commission ("SEC") on October 26, 2022, (the "First LP Registration Statement").
On February 13, 2023 we filed a registration statement with the SEC (the "Second LP Registration Statement") to register the sale of additional shares related to the Purchase Agreement. The Second LP Registration Statement became effective on July 13, 2023.

Macroeconomic Environment
Unfavorable conditions in the economy in the United States, Canada and abroad, including conditions resulting from changes in gross domestic product growth, labor shortages, supply chain disruptions, inflationary pressures, rising interest rates, financial and credit market fluctuations, banking collapses and related uncertainty, international trade relations, political turmoil, natural catastrophes, outbreaks of contagious diseases, warfare and terrorist attacks on the United States, Europe or elsewhere, including military actions affecting Russia, Ukraine or elsewhere, could cause a decrease in business investments on our products and negatively affect the growth of our business and our results of operations.
Key Components of Results of Operations
Revenue
26
Table of Contents
We primarily generate our revenue through subscription sales to access our QCaaS cloud platform and professional services that assist our customers in identifying and implementing applications that leverage our QCaaS cloud platform. QCaaS revenue is recognized on a ratable basis over the contract term, which generally ranges from one month to two years. Professional services revenue is primarily recognized based on a percentage of completion basis as services are being delivered.
We expect that there will be a decrease in our cloud based recurring QCaaS revenue as a percentage of total revenue in 2023 when compared to 2022 due to increased demand for professional services engagements. In subsequent periods, we expect that the general trend will be for QCaaS revenue as a percentage of total revenue to increase due to an increasing number of QCaaS agreements being driven by the completion of professional services engagements yielding production applications that require QCaaS services, as well as by customers that choose to access our Leap cloud service without utilizing our professional services organization.
Cost of Revenue
Our cost of revenue consists of expenses related to providing our QCaaS offering and delivering our professional services, specifically personnel-related expenses, including stock-based compensation, and costs associated with maintaining the cloud platform on which the QCaaS resides. The cost of revenue also includes depreciation and amortization related to our quantum computing systems and related software.
We expect our total cost of revenue to increase in absolute dollars in future periods, corresponding to our anticipated growth in professional services revenue and related headcount as well to support our customers and to maintain the QCaaS cloud offering. Because the costs of delivering our QCaaS cloud offering are less than the costs for our professional services, we anticipate that an increase of QCaaS revenue will increase our gross margin in the longer term.
Operating Expenses
Our operating expenses consist of research and development, general and administrative, and sales and marketing expenses.
Research and Development
Research and development expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation for personnel, fabrication costs, consulting and engineering services, lab supplies, and cloud computing resources and allocated facility costs for our research and development functions. Unlike a standard computer, design and development efforts continue throughout the useful life of our quantum computing systems to ensure proper calibration and optimal functionality. Research and development expenses also include purchased hardware components, fabrication and software costs related to quantum computing systems constructed for research purposes that do not have a high probability of providing near-term future economic benefits, and may have no alternate future use. We currently do not capitalize any research and development expenses. We expect to continue to make substantial investments in our research and development capabilities.
General and Administrative
General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation for personnel and outside professional services expenses including legal, audit and accounting services, insurance, other administrative expenses and allocated facility costs for our administrative functions. We expect to continue to invest in our general and administrative components, in particular in comprehensive compliance and governance functions, increased IT security and compliance, and enhanced internal controls over financial reporting.
Sales and Marketing
Sales and marketing expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation for personnel, direct advertising, marketing and promotional material costs, sales commission expense, consulting fees and allocated facility costs for our sales and marketing functions. We intend to continue to make significant investments in our sales and marketing organization to drive additional revenue, expand our global customer base, and broaden our brand awareness. We expect our sales and marketing expenses to continue to increase in absolute dollars for the foreseeable future as we invest in various go-to-market initiatives.
Other income (expense), net
Other income (expense), net is primarily comprised of change in fair value of warrant liabilities and debt, debt issuance costs, interest expense and foreign currency gains or losses.
27
Table of Contents
Results of Operations
The following table sets forth our results of operations for the periods indicated (in thousands):
Three Months Ended June 30,
(In thousands, except share and per share data) 2023 2022
Revenue $ 1,707  $ 1,371 
Cost of revenue 1,002  620 
          Total gross profit 705  751 
Operating expenses:
   Research and development 9,548  7,456 
   General and administrative 9,576  3,959 
   Sales and marketing $ 2,488  $ 1,739 
   Total operating expenses 21,612  13,154 
          Loss from operations (20,907) (12,403)
Other income (expense), net:
   Interest expense $ (781) $ (1,479)
   Change in fair value of warrant liabilities $ (2,150) $ — 
  Change in fair value of Term Loan (345) — 
   Term Loan debt issuance costs (1,393) — 
   Other income (expense), net (322) 533 
Total other income (expense), net $ (4,991) $ (946)
   Net loss $ (25,898) $ (13,349)
Foreign currency translation adjustment, net of tax (66) 32 
          Net comprehensive loss $ (25,964) $ (13,317)
Six Months Ended June 30,
(In thousands, except share and per share data) 2023 2022
Revenue $ 3,290  $ 3,083 
Cost of revenue 2,164  1,235 
          Total gross profit 1,126  1,848 
Operating expenses:
   Research and development 20,463  14,260 
   General and administrative 20,872  7,606 
   Sales and marketing 5,388  3,339 
   Total operating expenses 46,723  25,205 
          Loss from operations (45,597) (23,357)
Other income (expense), net:
   Interest expense (1,235) (2,262)
   Change in fair value of warrant liabilities (1,512) — 
  Change in fair value of Term Loan (345) — 
   Term Loan debt issuance costs (1,393) — 
   Other income (expense), net (424) 353 
Total other income (expense), net $ (4,909) $ (1,909)
   Net loss $ (50,506) $ (25,266)
Foreign currency translation adjustment, net of tax (85) (38)
          Net comprehensive loss $ (50,591) $ (25,304)

Comparison of the Three Months Ended June 30, 2023 and 2022
28
Table of Contents
Revenue
Revenue increased $0.3 million, or 25%, to $1.7 million for the three months ended June 30, 2023 as compared to $1.4 million for the three months ended June 30, 2022. The increase in revenue was primarily driven by an increase in delivery of professional services that enable our customers to identify and implement applications that leverage our QCaaS cloud platform.
Cost of Revenue
Cost of revenue increased $0.4 million, or 62%, to $1.0 million for the three months ended June 30, 2023 as compared to $0.6 million for the three months ended June 30, 2022. The increase in cost of revenue was driven primarily by an increase in personnel related costs, including $0.2 million related to stock-based compensation expense.
Operating Expenses

Research and Development Expenses
Three Months Ended June 30, Change
(In thousands, except percentages) 2023 2022 Amount %
   Research and development $ 9,548  $ 7,456  $ 2,092  28  %
Research and development expenses increased by $2.1 million, or 28% to $9.5 million for the three months ended June 30, 2023 compared to $7.5 million for the three months ended June 30, 2022. The increase was primarily a result of our continuous efforts to broaden the functionality of our QCaaS cloud platform and improve the reliability, availability and scalability of our cloud platform. In particular, our personnel-related expenses increased $2.1 million (including $1.6 million related to stock-based compensation expense) and wafer fabrication costs increased $0.3 million due to higher activity rates. These increases were offset by decreases in repairs and maintenance costs of $0.2 million and a reduction in supply purchases of $0.1 million.
General and Administrative Expenses
Three Months Ended June 30, Change
(In thousands, except percentages) 2023 2022 Amount %
   General and administrative $ 9,576  $ 3,959  $ 5,617  142  %
General and administrative expenses increased $5.6 million, or 142%, to $9.6 million for the three months ended June 30, 2023 as compared to $4.0 million for the three months ended June 30, 2022. The increase was primarily a result of operating as a public company. In particular, legal, accounting and consulting fees increased $2.3 million, our personnel-related expenses increased $2.7 million (including $2.0 million related to stock-based compensation expense), and Directors and Officers insurance costs increased by $0.8 million.
Sales and Marketing Expenses
Three Months Ended June 30, Change
(In thousands, except percentages) 2023 2022 Amount %
   Sales and marketing $ 2,488  $ 1,739  $ 749  43  %
Sales and marketing expenses increased $0.7 million, or 43%, to $2.5 million for the three months ended June 30, 2023 as compared to $1.7 million for the three months ended June 30, 2022. The increase was primarily a result of higher personnel-related expenses of $0.8 million, including $0.1 million related to stock-based compensation expense.
Other Income (Expense), net
Three Months Ended June 30, Change
2023 2022 Amount %
   Other income (expense), net $ (4,991) $ (946) $ (4,045) 428  %
Other expense, net increased by $4.0 million or 428%, to $5.0 million for the three months ended June 30, 2023 as compared to $0.9 million for the three months ended June 30, 2022, with the increases comprised of changes in fair value of warrant liabilities of $2.2 million, foreign exchange losses of $0.9 million, debt issuance costs of $1.4 million and change in fair value of Term Loan of $0.3 million. The increases were partly offset by lower interest expense of $0.8 million due to a lower debt balance.
29
Table of Contents

Comparison of the Six Months Ended June 30, 2023 and 2022
Revenue
Revenue increased $0.2 million, or 7%, to $3.3 million for the six months ended June 30, 2023 as compared to $3.1 million for the six months ended June 30, 2022. The increase in revenue was primarily driven by an increase in delivery of professional services that enable our customers to identify and implement applications that leverage our QCaaS cloud platform, partly offset by lower QCaaS revenue due to non-renewal for several customer contracts that were partially replaced with new customer contracts.
Cost of Revenue
Cost of revenue increased $0.9 million, or 75%, to $2.2 million for the six months ended June 30, 2023 as compared to $1.2 million for the six months ended June 30, 2022. The increase in cost of revenue was primarily driven by an increase in increase in personnel related costs, including $0.6 million in stock-based compensation costs.

Operating Expenses
Research and Development Expenses
Six Months Ended June 30, Change
2023 2022 Amount %
   Research and development 20,463  14,260  $ 6,203  43  %
Research and development expenses increased by $6.2 million, or 43%, to $20.5 million for the six months ended June 30, 2023 compared to $14.3 million for the six months ended June 30, 2022. The increase was primarily a result of our continuous efforts to broaden the functionality of our QCaaS cloud platform and improve the reliability, availability and scalability of our cloud platform. In particular, our personnel-related expenses increased $5.1 million (including $4.2 million related to stock-based compensation expense), and our wafer fabrication costs increased $1.1 million due to higher activity rates.

General and Administrative Expenses
Six Months Ended June 30, Change
2023 2022 Amount %
   General and administrative $ 20,872  $ 7,606  $ 13,266  174  %
General and administrative expenses increased $13.3 million, or 174%, to $20.9 million for the six months ended June 30, 2023 as compared to $7.6 million for the six months ended June 30, 2022. The increase was primarily a result of operating as a public company. In particular, our legal, accounting, tax and consulting fees increased $4.8 million, our personnel-related expenses increased $6.2 million (including $4.7 million related to stock-based compensation expense), Directors and Officers insurance costs increased $1.4 million and SEC Filing fees increased $0.5 million.
Sales and Marketing Expenses
Six Months Ended June 30, Change
2023 2022 Amount %
   Sales and marketing $ 5,388  $ 3,339  $ 2,049  61  %
Sales and marketing expenses increased $2.0 million, or 61%, to $5.4 million for the six months ended June 30, 2023 as compared to $3.3 million for the three months ended June 30, 2022. The increase was primarily a result of our efforts to expand our go-to-market initiatives. The increase was comprised of higher personnel-related expenses of $1.3 million (including $0.4 million related to stock-based compensation expense), promotional costs of $0.3 million and consulting of $0.3 million.
Other Income (Expense), net
30
Table of Contents
Six Months Ended June 30, Change
2023 2022 Amount %
   Other income (expense), net $ (4,909) $ (1,909) $ (3,000) 157  %
Other Income (Expense)
Other expense, net increased by $3 million or 157%, to $4.9 million for the six months ended June 30, 2023 as compared to $1.9 million for the six months ended June 30, 2022, with the increases comprised of change in fair value of warrant liabilities of $1.5 million, foreign exchange losses of $0.7 million, debt issuance costs of $1.4 million and change in fair value of Term Loan of $0.3 million. The increases were partly offset by lower interest expense of $1.2 million due to a lower debt balance.
Liquidity and Capital Resources
We have incurred net losses and experienced negative cash flows from operations since inception. To date, our primary sources of capital have been through private placements of convertible preferred shares, private placements of common stock revenue from the sale of our products and services, government assistance and debt financing. During the six months ended June 30, 2023 and 2022, we incurred net losses of $50.5 million and $25.3 million, respectively. We expect to incur additional losses and higher operating expenses for the foreseeable future as we continue to invest in research and development and go-to-market programs. We have determined that additional financing will be required to fund our operations for the next 12 months and our ability to continue as a going concern is dependent upon obtaining additional capital and financing.
Our primary uses of cash are to fund our operations as we continue to grow our business. We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations. Until such time as we can generate significant revenue from sales of our QCaaS offering and our professional services, we expect to finance our cash needs through public and/or private equity (including sales pursuant to the Purchase Agreement) and/or debt financings or other capital sources. However, we may be unable to raise sufficient funds or enter into such other arrangements, when needed, on favorable terms, or at all. In particular, uncertain and unfavorable conditions in the United States and global macroeconomic environment, including inflationary pressures, rising interest rates, banking collapses, and financial and credit market fluctuations, could reduce our ability to access capital on favorable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be, or could be, diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, or substantially reduce our quantum computing development and go-to-market efforts.
As of June 30, 2023, we have 17,916,609 Warrants outstanding, each Warrant being exercisable for 1.4541326 Common Shares of the Company at an exercise price of $11.50. Whether warrant holders will exercise their Warrants, and therefore the amount of cash proceeds we would receive upon exercise, is dependent upon the trading price of the Common Shares. Therefore, if and when the trading price of the Common Shares is less than approximately $7.91, the effective exercise price of the Warrants per one Common Share we expect that warrant holders will not exercise their Warrants. Our Common Shares have closed below $7.91 since October 11, 2022. Therefore, we do not expect warrant holders to exercise their Warrants in the short-term and as such we do not expect to rely on the cash exercise of Warrants to fund our operations. Instead, we intend to rely on other sources of cash discussed below to continue to fund our operations. If we are unable to raise additional funds through equity or debt financings when needed, we will be required to delay, limit, or substantially reduce our quantum computing development and go-to-market efforts.
Term Loan and Security Agreement
On April 13, 2023, we entered into the Term Loan, by and between us and PSPIB Unitas Investments II Inc. (the "Lender" or "PSPIB") as the lender. Under the Term Loan, loans in aggregate principal amount of $50.0 million are to be made available to us in three tranches, subject to certain terms and conditions and a 2.0% drawdown fee. The Term Loan matures on March 31, 2027 and is secured by a first-priority security interest in substantially all of our assets and contains certain operational and financial covenants, including a financial covenant that measures our revenue against certain minimum percentages of budgeted revenue per quarter. The Term Loan requires that any proceeds from the issuance of Common Shares under the Purchase Agreement be applied towards the repayment of advances under the Term Loan in addition to a premium payment equal to 10.0% of the amount then prepaid to the Lender, except as modified by the amendment to the Term Loan as described below. The Term Loan is subject to a prepayment premium due to the Lender equal to 3% of the amount prepaid/repaid within the first year of the Closing Date, 2% in the second year, 1% in the third year and no prepayment premium thereafter. At our discretion, the Term Loan bears interest on a monthly basis at either (i) 10.0% payable in cash, or (ii) 11.0% payable in kind (PIK), with the latter added to the principal value of the Term Loan.
31
Table of Contents
The first two tranches of the Term Loan, each amounting to $15.0 million in principal, were advanced to us on April 14, 2023 and July 13, 2023, respectively, with the third tranche of $20.0 million to be made available to us on October 10, 2023, subject to certain conditions. Prior to PSPIB's advance of the first tranche, the Company satisfied several closing conditions including the provision of a cash flow forecast and the board of directors' retention of an advisor. The Lender agreed to modify certain conditions to the funding of the second tranche of the Term Loan, including delaying the delivery of a board-approved operating budget and plan for the Company’s fiscal years 2023 through 2027 to August 31, 2023; modifying the condition that, prior to the funding of the second tranche, the Company shall have nominated an additional director that is either an employee of PSPIB or an independent director selected from PSPIB nominees to require such appointment at a later time at PSPIB’s option; and modifying notice deadline requirements for the registration or filings of intellectual property. PSPIB has also agreed to waive certain covenants under the Term Loan that the Company did not meet, including the minimum revenue financial covenant for the second fiscal quarter ended June 30, 2023. The second tranche was advanced to us after we satisfied several closing conditions, including providing the Lender with an intellectual property valuation report and SIF’s consent to the grant of security interests in D-Wave's project intellectual property associated with the SIF Loan. There can be no assurance that the Company will be able to meet the conditions necessary to draw on the third tranche or will be able to comply with the covenants of the Term Loan, or that PSPIB will agree to waive covenants under the Term Loan in the future. The third tranche, that shall be available to us as of October 10, 2023, is subject to us closing a $25.0 million non-dilutive financing on terms reasonably acceptable to the Lender, and the intellectual property valuation report submitted as a condition precedent to the second tranche and board-approved operating budget for 2023 through 2027 being submitted by August 31, 2023 both remaining satisfactory to the Lender.
The Term Loan was amended on July 20, 2023 such that the Company may issue up to $50.0 million under the Lincoln Park Purchase Agreement described below without the requirement to pay down the Term Loan to the extent that the proceeds under the Purchase Agreement are received prior to October 18, 2023. As amended, the Term Loan requires that any proceeds from the issuance of Common Shares under the Purchase Agreement in excess of $50.0 million shall be applied towards the repayment of advances under the Term Loan in addition to a premium payment equal to 10% of the amount then prepaid to the Lender.
Lincoln Park Purchase Agreement
The Purchase Agreement with Lincoln Park may provide the Company with additional liquidity to fund the business, subject to the conditions set forth in the agreement, including volume limitations tied to periodic market prices, ownership limitations restricting Lincoln Park from owning more than 9.9% of the then total outstanding Common Shares and a floor price of $1.00 at which the Company may not sell to Lincoln Park any Common Shares. When we sell shares to Lincoln Park, Lincoln Park may resell all, some, or none of those Common Shares at any time or from time to time in its discretion. For the six months ended June 30, 2023, the Company has received $15.7 million in proceeds through the issuance of 13,239,654 Common Shares to Lincoln Park under the Purchase Agreement. On February 13, 2023, the Company filed an S-1 registration statement with the SEC to register an additional 35.0 million shares of Common Shares under the Purchase Agreement with Lincoln Park. The registration statement became effective July 13, 2023 and as of August 7, 2023 the Company has since raised an additional $34.2 million through the issuance of 16,590,877 common shares under the Purchase Agreement. In order for the Company to issue common shares under the Purchase Agreement, the Company's share price must be above the floor price of $1.00 per share. There is no assurance that the floor price will not fall below $1.00 preventing the Company from being able to make sales to Lincoln Park in the future.
To the extent that sufficient capital is not obtained through the cash received in connection with the Term Loan and the issuance of Common Shares under the Purchase Agreement, management will be required to obtain additional capital through the issuance of additional debt and/or equity, or other arrangements. However, there can be no assurance that D-Wave will be able to raise additional capital when needed or under acceptable terms. The issuance of additional equity may dilute existing stockholders and newly issued shares may contain senior rights and preferences compared to the currently outstanding Common Shares. Any future debt may contain covenants and limit D-Wave’s ability to pay dividends or make other distributions to stockholders.
Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in the section titled “Risk Factors" in this Report.
Cash Flows
The following table sets forth our cash flows for the periods indicated (in thousands):
32
Table of Contents
Six months ended June 30,
2023 2022
Net cash (used in) provided by:
Operating Activities $ (29,044) $ (21,499)
Investing Activities (79) (218)
Financing Activities 29,657  22,765 
Effect of exchange rate changes on cash and cash equivalents (85) (65)
Net (decrease) increase in cash and cash equivalents $ 449  $ 983 
Cash Flows Used in Operating Activities
Our cash flows from operating activities are significantly affected by the growth of our business, and are primarily related to research and development, sales and marketing and general and administrative activities. Our operating cash flows are also affected by our working capital needs to support growth in personnel-related expenditures and fluctuations in accounts payable, accounts receivable and other current assets and liabilities.
Net cash used in operating activities during the six months ended June 30, 2023 was $29.0 million, resulting primarily from a net loss of $50.5 million, adjusted for non-cash charges of $1.0 million in depreciation and amortization, including amortization of operating right of use assets, $11.5 million in stock-based compensation, $1.5 million in change in fair value of public and private warrants, $1.2 million in non-cash interest and $4.9 million in working capital adjustments.
Net cash used in operating activities during the six months ended June 30, 2022 was $21.5 million, resulting primarily from a net loss of $25.3 million, adjusted for non-cash charges of $1.2 million in depreciation and amortization including amortization of operating right of use assets, $1.6 million in stock-based compensation, $1.7 million in non-cash interest on government loans, $0.5 million in other non-cash activities and $1.2 million in working capital adjustments.
Cash Flows Used in Investing Activities
Net cash used in investing activities during the six months ended June 30, 2023 was $0.1 million, primarily representing additions of $0.1 million in property and equipment.
Net cash used in investing activities during the six months ended June 30, 2022 was $0.2 million, primarily representing additions of $0.2 million in property and equipment.
Cash Flows Provided by Financing Activities
Net cash provided by financing activities during the six months ended June 30, 2023 was $29.7 million, primarily reflecting proceeds from the Lincoln Park Purchase Agreement of $15.7 million, net proceeds from the first tranche of the Term Loan of $14.4 million, and stock option exercise proceeds of $1.2 million, partially offset by payments for financed Directors and Officers Insurance premiums of $1.8 million.

Net cash provided by financing activities during the six months ended June 30, 2022 was $22.8 million, primarily reflecting net proceeds received from the Venture Loan and Security Agreement, dated as of March 3, 2022, between D-Wave and its subsidiaries and PSPIB, as lender, for $19.9 million, and net proceeds received from the SIF Loan for $3.2 million.
Contractual Obligations and Commitments
As of June 30, 2023, there have been no material changes with regard to contractual obligations from those disclosed in our "Management's Discussion and Analysis on Financial Condition and Results of Operations—Contractual Obligations and Commitments" in our Annual Report on Form 10-K for the year ended December 31, 2022.

Critical Accounting Policies and Estimates
There have been no material changes to our critical accounting policies from those disclosed in our "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates" in our Annual Report on Form 10-K for the year ended December 31, 2022.
Recent Accounting Pronouncements
See Note 2 of our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information regarding recently issued accounting pronouncements.
33
Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk
During the six months ended June 30, 2023, there were no material changes from the market risk disclosures in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2022.
Item 4. Controls and Procedures
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
Evaluation of Disclosure Controls and Procedures
In accordance with the Exchange Act Rules 13a-15(e) and 15d-15(e), we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2023. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, due to a material weakness in our internal control over financial reporting specifically related to D-Wave’s control environment in relation to our financial statement close process (i.e., lack of sufficient accounting and financial reporting personnel with requisite knowledge and experience in the application of complex areas of GAAP and SEC rules to facilitate accurate and timely financial reporting and to perform sufficient review over certain financial statement areas), as previously disclosed in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2022, our disclosure controls and procedures were not effective as of the end of the period covered by this Report.
Notwithstanding the material weakness described above, we have concluded that our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with U.S. GAAP for the periods presented therein.
Remediation Efforts on Previously Reported Material Weakness
We are implementing measures designed to improve our internal controls over financial reporting to remediate this material weakness including adding additional qualified accounting personnel with experience with complex GAAP and SEC rules, engaging consultants to assist with the financial statement close process, and segregating duties among accounting personnel to enable adequate review controls. The primary costs associated with such measures are corresponding recruiting and additional salary and consulting costs, which are difficult to estimate at this time but which may be significant. These additional resources and procedures are intended to enable us to broaden the scope and quality of our internal review of underlying information related to financial reporting and to formalize and enhance our internal control procedures.
The material weakness will not be considered remediated until our remediation plan has been fully implemented, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively. We are continuing to work on the implementation of our remediation plan, following which we will continue to test such controls over time.
Changes in Internal Control Over Financial Reporting
Other than the ongoing remediation to address the material weakness described above, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), during the three months ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


34
Table of Contents
Part II - Other Information
Item 1. Legal Proceedings
To the knowledge of our management, there is no litigation currently pending or contemplated against us, any of our officers or directors in their capacity as such or against any of our property.
From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.
Item 1A. Risk Factors
There have been no material changes from the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on April 18, 2023, with the exception of the risk factor discussed below.
If we are unable to retain a replacement independent registered public accounting firm in sufficient time to review the Company’s Quarterly Report on Form 10-Q for the quarterly period ending September 30, 2023 (the “Q3 10-Q”), we may face adverse action from the SEC and/or the NYSE.
As disclosed in the Company’s Current Report on 8-K that the Company filed with the SEC on June 13, 2023, PricewaterhouseCoopers LLP (Canada) (“PwC”) notified the Company on June 7, 2023 of PwC's decision to decline to stand for re-election as the independent registered public accounting firm of the Company. Although PwC has declined to stand for re-election, it has agreed to maintain its relationship with the Company for the review of this Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2023.
The Company is currently interviewing potential replacement independent registered public accounting firms and is hopeful of retaining one in sufficient time for such firm to review the Q3 10-Q. If the Company is unable to do so, however, it may be unable to file its Q3 10-Q on a timely basis or at all. Such a deficient Q3 10-Q could result in SEC sanctions, a suspension or delisting from the NYSE, or both. Any such SEC sanctions or NYSE suspension or delisting would likely have a negative effect on the price of our securities, would impair your ability to sell or purchase our securities when you wish to do so and would also likely materially affect our ability to raise capital on favorable terms in the future.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Not applicable.
Item 6. Exhibits
The documents listed below are incorporated by reference or are filed with this Quarterly Report on Form 10-Q, in each case as indicated therein (numbered in accordance pursuant to Item 601 of Regulation S-K).

Exhibit No.
Description
Incorporated by Reference Exhibits
Filer
Form
Exhibit
Filing Date
35
Table of Contents
10.1! D-Wave Quantum Inc. 8-K 10.1 April 19, 2023
10.2 D-Wave Quantum Inc. 8-K 10.1 April 24, 2023
10.3 D-Wave Quantum Inc. 8-K 10.1 June 2, 2023
10.4
10.5 D-Wave Quantum Inc. 8-K 10.1 July 20, 2023
10.6 D-Wave Quantum Inc. 8-K 10.1 July 21, 2023
10.7
10.8†
10.9†
10.10†
10.11†
10.12†
10.13†
10.14†
31.1*
31.2*
32.1#
32.2#
101.INS *
Inline XBRL Instance Document
101.SCH *
Inline XBRL Taxonomy Schema Document
101.CAL *
Inline XBRL Taxonomy Calculation Linkbase Document
101.DEF *
Inline XBRL Taxonomy Definition Linkbase Document
36
Table of Contents
101.LAB *
Inline XBRL Taxonomy Label Linkbase Document
101.PRE *
Inline XBRL Taxonomy Presentation Linkbase Document
104*
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith.

! Certain portions of this exhibit (indicated by “[*****]”) have been redacted pursuant to Regulation S-K, Item 601(a)(6).
# The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
†Indicates management contract or compensatory plan or arrangement.




37
Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
D-Wave Quantum Inc.
August 10, 2023 By: /s/ Alan Baratz
Alan Baratz
President and Chief Executive Officer
(Principal Executive Officer)
By: /s/ John M. Markovich
John M. Markovich
Chief Financial Officer
(Principal Financial and Accounting Officer)
38
EX-10.4 2 exhibit104-q22023.htm EX-10.4 Document
Execution Version
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT

AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of June 16, 2023, by and between D-WAVE QUANTUM INC., a Delaware corporation (the “Borrower”), and the Lender (as defined below) party hereto.
W I T N E S S E T H:
WHEREAS, the Borrower, D-Wave Systems Inc., a British Columbia corporation, D-Wave US Inc., a Delaware corporation, D-Wave Government Inc., a Delaware corporation, D-Wave Commercial Inc., a Delaware corporation, D-Wave International Inc., a Canadian corporation, D-Wave Quantum Solutions Inc., a Canadian corporation, Omni Circuit Boards Ltd., a British Columbia corporation, DPCM Capital, Inc., a Delaware corporation, 1372929 B.C. Ltd, a British Columbia corporation, 1372934 B.C. LTD., a British Columbia corporation, DWSI Canada Holdings ULC, a British Columbia corporation, D-Wave Quantum Technologies Inc., a British Columbia corporation, and each other Person hereafter joined thereto as a guarantor (collectively or individually, as the context may dictate, the “Guarantors” and together with the Borrower, the “Loan Parties”) and PSPIB Unitas Investments II Inc., a Canadian corporation, as Collateral and as Lender (the “Lender”), are parties to that certain Loan and Security Agreement, dated as of April 13, 2023 (as amended, modified, supplemented, renewed, restated or replaced from time to time, the “Existing Loan Agreement”);
WHEREAS, the Borrower has requested certain amendments to the Existing Loan Agreement, and the Lender party hereto has agreed to such amendments, subject to the terms and conditions hereof; and
NOW, THEREFORE, in consideration of the covenants and agreements contained herein, as well as other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
1.Defined Terms. Capitalized terms used but not defined herein shall have the respective meanings assigned to such terms in the Existing Loan Agreement, as amended by this Amendment (the “Amended Loan Agreement”).
2.Amendments to Existing Loan Agreement. Subject to, and in accordance with, the terms and conditions set forth herein, including the satisfaction (or waiver by the Lender) of all conditions precedent set forth in Section 3 below, the Existing Loan Agreement is hereby amended as follows:
(a)The definition of “Liquidity” in the Existing Loan Agreement is hereby amended and restated as follows:
“Liquidity” means, as of any date of determination, the aggregate amount of unrestricted cash and Cash Equivalents of the Loan Parties (i) held in a deposit account subject to an Account Control Agreement in favor of the Collateral Agent, and (ii) held in the Foreign Bank Accounts in an aggregate amount of up to $300,000; provided, that no cash or Cash Equivalents held or deposited in respect of utility deposits shall be included in the calculation of Liquidity.
(b)Section 3.3(a)(ii) of the Existing Loan Agreement is hereby amended and restated as follows:
“(ii) As soon as reasonably practicable, but in no event later than sixty (60) days following the advance of Loan A, a Landlord Agreement for each location (other than the property located at 4601 Canada Way, Burnaby, BC, Canada, a building that Borrower subleases, that contains no books or records or Collateral with such lease terminating on June 30, 2023) where Borrower’s books and records and the Collateral is located (unless Borrower is the fee owner thereof), in form and substance reasonably acceptable to the Collateral Agent; provided, however, that to the extent the lease for 4601 Canada Way, Burnaby, BC, Canada is renewed or extended beyond June 30, 2023, the Borrower shall use its reasonable commercial efforts to provide the Collateral Agent with a Landlord Agreement for such location in no event later than sixty (60) days following July 1, 2023;”

US-DOCS\141593351.3
WEIL:\99194017\5\68582.0400

(c)Section 7.13(a) of the Existing Loan Agreement is hereby amended and restated as follows:
“(a)    Maintain any deposit account or securities account, except accounts with respect to which Collateral Agent and the applicable depository institution have entered into an Account Control Agreement; provided that with respect to deposit accounts maintained at institutions in Canada, each Loan Party shall use commercially reasonable efforts to satisfy this provision within fifteen (15) Business Days after the date hereof. Notwithstanding the foregoing, (i) the non-Loan Party Subsidiaries shall be permitted to maintain Foreign Bank Accounts, over which the Lenders do not have a perfected security interest, provided, however, that the aggregate amount on deposit in all such Foreign Bank Accounts shall not exceed $300,000 at any time, other than due to receipt of customer payments so long as D-Wave shall initiate fund transfers within five (5) Business Days after the date of receipt of such customer funds to ensure compliance with the $300,000 limit on or prior to the sixth (6th) Business Day after the date of receipt of such customer funds, and (ii) no Account Control Agreement shall be required for a single deposit account at Wells Fargo Bank (account no. 9939397451) that secures the commercial credit card of D-Wave Systems Inc., provided that such account does not have an account balance in excess of $75,000.”
3.Condition to Effectiveness. The effectiveness of this Amendment is subject to the Lender having received executed counterparts hereof from the Borrower and the Lender (the date of such satisfaction (or waiver) being the “Amendment Effective Date”).
4.Representations and Warranties. Each Loan Party hereby represents and warrants, on and as of the Amendment Effective Date and after giving effect to this Amendment, that:
(a)the representations and warranties set forth in Section 5 of the Existing Loan Agreement and in each other Loan Document are true and correct in all material respects on and as of the Amendment Effective Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case they shall be true and correct in all material respects as of such earlier date; provided that any representation and warranty that is qualified as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates;
(b)no event has occurred or exists that would constitute a Default or an Event of Default;
(c)this Amendment has been duly executed and delivered by the Borrower and this Amendment and the Amended Loan Agreement constitute the legal, valid and binding obligations of Borrower, enforceable against it in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application relating to or affecting the enforcement of creditors’ rights or by general principles of equity.
(d)the execution, delivery and performance of this Amendment and the performance by each Loan Party has been duly authorized by all necessary action on the part of Borrower and each Subsidiary. No authorization, consent, approval, license or exemption of, and no registration, qualification, designation, declaration or filing with, or notice to, any Person is, was or will be necessary to (a) the valid execution and delivery of this Amendment, or (b) the performance of Borrower’s or any Subsidiary’s obligations under this Amendment or the Amended Loan Agreement.
5.Effects on Loan Documents.
(a)On and after the effectiveness of this Amendment, each reference in any Loan Document to “the Loan Agreement” shall mean and be a reference to the Amended Loan Agreement and each reference in the Existing Loan Agreement to “this Agreement,” “hereunder,” “hereof” or words of like import shall mean and be a reference to the Amended Loan Agreement.
                        - 2 -


(b)Except as specifically amended herein, all Loan Documents (including the guaranty and all Liens granted thereunder in respect of the Obligations) shall continue to be in full force and effect and are hereby in all respects ratified and confirmed.
(c)The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Lender or the Collateral Agent under any of the Loan Documents, nor constitute a waiver of any provision of the Loan Documents (except as expressly provided herein) or in any way limit, impair or otherwise affect the rights and remedies of the Collateral Agent or the Lenders under the Loan Documents. This Amendment and the Amended Loan Agreement shall not constitute a novation of the Existing Loan Agreement or the other Loan Documents.
(d)The Loan Parties and the other parties hereto hereby acknowledge and agree that, on and after the Amendment Effective Date, this Amendment shall constitute a Loan Document for all purposes of the Amended Loan Agreement.
6.CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, AND THE TERMS OF SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW SHALL APPLY. PURSUANT TO SECTION 5-1402 OF THE NEW YORK GENERAL OBLIGATION LAWS, EACH OF BORROWER AND LENDER HEREBY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK. BORROWER AND LENDER HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AMENDMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS.
7.Headings. Section headings used herein are for convenience of reference only, are not part of this Amendment and are not to affect the construction of, or to be taken into consideration in interpreting, this Amendment.
8.Successors and Assigns. The provisions of this Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted by the Amended Loan Agreement.
9.Severability. In the event any one or more of the provisions contained in this Amendment should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. The parties shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.
10.Counterparts. This Amendment may be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Any signature delivered by a party by facsimile or other electronic means of transmission (including email transmission of a PDF copy) shall be deemed to be an original signature hereto.
11.Entire Agreement. This Amendment and the Loan Agreement as amended hereby and the other Loan Documents constitute the entire agreement, and supersede any prior agreements and contemporaneous oral agreements, of the parties concerning their subject matter.
[Signature Pages Follow]
                        - 3 -


IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed under seal by their duly authorized officers, all as of the day and year first written above.
BORROWER:
D-WAVE QUANTUM INC.
By:___/s/ Alan Baratz Name: Alan Baratz Title: Chief Executive Officer PSPIB UNITAS INVESTMENTS II INC. as a Lender


        
[Signature Page to First Amendment]

LENDER:
By: /s/ Michael Larkin    
Name: Michael Larkin
Title: Authorized Signatory
By: /s/ Jonathan Ostrzega    
Name: Jonathan Ostrzega
Title: Authorized Signatory


        
[Signature Page to First Amendment]
EX-10.7 3 exhibit107-q22023.htm EX-10.7 Document

LIMITED WAIVER TO LOAN AND SECURITY AGREEMENT
LIMITED WAIVER TO LOAN AND SECURITY AGREEMENT (this “Waiver”), dated as of July 28, 2023, by and between D-WAVE QUANTUM INC., a Delaware corporation (the “Borrower”), and the Lender (as defined below) party hereto.
W I T N E S S E T H:
WHEREAS, the Borrower, D-Wave Systems Inc., a British Columbia corporation, D-Wave US Inc., a Delaware corporation, D-Wave Government Inc., a Delaware corporation, D-Wave Commercial Inc., a Delaware corporation, D-Wave International Inc., a Canadian corporation, D-Wave Quantum Solutions Inc., a Canadian corporation, Omni Circuit Boards Ltd., a British Columbia corporation, DPCM Capital, Inc., a Delaware corporation, 1372929 B.C. Ltd, a British Columbia corporation, 1372934 B.C. LTD., a British Columbia corporation, DWSI Canada Holdings ULC, a British Columbia corporation, D Wave Quantum Technologies Inc., a British Columbia corporation, and each other Person hereafter joined thereto as a guarantor (collectively or individually, as the context may dictate, the “Guarantors” and together with the Borrower, the “Loan Parties”) and PSPIB Unitas Investments II Inc., a Canadian corporation, as Collateral and as Lender (the “Lender”), are parties to that certain Loan and Security Agreement, dated as of April 13, 2023 (as amended pursuant to that certain First Amendment to Loan and Security Agreement dated as of June 16, 2023, that certain Limited Waiver and Second Amendment to Loan and Security Agreement dated as of July 13, 2023, and that certain Third Amendment to Loan and Security Agreement dated as of July 20, 2023 and as further amended, modified, supplemented, renewed, restated or replaced from time to time, the “Existing Loan Agreement”);
WHEREAS, Section 7.16(b)(i) of the Loan Agreement provides that the Borrower shall not permit or cause the consolidated revenue of the Borrower and its Subsidiaries to be, for the fiscal quarter ending June 30, 2023, less than 75% of the consolidated revenue set forth in Borrower’s board-approved operating budget as of the Closing Date with respect to the fiscal quarter ending June 30, 2023, tested at quarter-end (the “2023 Q2 Permitted Variance Covenant);
WHEREAS, the Borrower will not meet the requirements of the 2023 Q2 Permitted Variance Covenant and Lender has agreed to waive the 2023 Q2 Permitted Variance Covenant, subject to the terms and conditions hereof;
NOW THEREFORE, in consideration of the covenants and agreements contained herein, as well as other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
1.Capitalized terms used but not defined herein shall have the respective meanings assigned to such terms in the Existing Loan Agreement.
2.Subject to the terms and conditions set forth herein, the Lender hereby waives the 2023 Q2 Permitted Variance Covenant.
3.For certainty, the waiver provided in Section 2 hereof is provided solely in respect of the 2023 Q2 Permitted Variance Covenant and no other obligation, requirement or right of the Lender under the Loan Agreement is being waived or affected and all of the terms of the Loan Agreement and all other Loan Documents shall remain in full force and effect. The Lender expressly reserves all rights, powers and discretions which it may have under the Loan Agreement or any other Loan Document.
4.This Waiver constitutes a Loan Document for the purposes of the Loan Agreement.
5.Time is of the essence of this Waiver.

2

6.This Waiver will enure to the benefit of and be binding upon the respective successors and permitted assigns of the parties.
7.This Waiver is governed by and will be construed in accordance with the laws of the State of New York. Section 15 of the Loan Agreement applies to this Waiver (mutatis mutandis).
8.This Waiver may be executed by the parties hereto in one or more counterparts, each of which shall be deemed to be an original and all of which will constitute together the one and the same agreement.

[Remainder of page intentionally blank.]



IN WITNESS WHEREOF the parties hereto have hereunto set their hands and seals as of the day and year first above written.
BORROWER:

D-WAVE QUANTUM INC.

By: /s/ Alan Baratz____________________________
Name:    Alan Baratz
Title:    President & CEO



    Signature Page - Consent


LENDER:

PSPIB UNITAS INVESTMENTS II INC.

By:/s/ Michael Larkin_________________________
Name:    Michael Larkin
Title:    Authorized Signatory

By: /s/ Jonathan Ostrzega______________________
Name:    Jonathan Ostrzega
Title:    Authorized Signatory



    Signature Page - Consent

EX-10.8 4 exhibit108-q22023.htm EX-10.8 exhibit108-q22023














































EX-10.9 5 exhibit109-q22023.htm EX-10.9 exhibit109-q22023














































EX-10.10 6 exhibit1010-q22023.htm EX-10.10 exhibit1010-q22023














































EX-10.11 7 exhibit1011-q22023.htm EX-10.11 exhibit1011-q22023


































































EX-10.12 8 exhibit1012-q22023.htm EX-10.12 exhibit1012-q22023




D-Wave Commercial Inc. 2650 E Bayshore Road Palo Alto, California USA 94303 www.dwavesys.com Page 2 of 9 and be assigned new reporting relationships. Any major change in the location of your employment will be subject to expense reimbursement in accordance with the Company’s policies. (c) Work Permit: Employment with the Company is subject to your obtaining and maintaining a valid permit to work in the United States during the entire period of your employment with the Company. You agree and undertake to provide documentation to the Company establishing your authority to work in the United States no later than the Commencement Date and at any time during your employment upon request from the Company and to immediately inform the Company of any changes to your work permit. Your failure to secure and maintain a valid permit to work in the United States may result in the Company’s immediate termination of this Agreement, at the Company’s sole discretion. (d) Scope and Hours of Work: During your employment, and subject to the Company’s business needs, you will perform at least 40 hours per week of work on such dates and times as determined by the Company in its sole discretion. While working you will devote your full time, attention and abilities to the effective and competent performance of your duties and responsibilities and you will give the Company the full benefit of your knowledge, expertise, technical skill and ingenuity. You are required to work such hours as are necessary to properly and effectively perform your duties and this may involve working hours that fall outside your usual working hours. Your base salary is paid to you in full and final compensation for all hours that you work for the Company, and you are not entitled to overtime pay or to time off in lieu. 3. Compensation: (a) Salary: You will be paid an annual base salary of USD$180,000.00, payable in equal instalments on the 15th and last day of each month, less all required or permitted withholdings and remissions, according to the Company’s regular payroll schedule (the “Salary”). (b) Performance Bonus: You will be eligible to participate in the D-Wave 2022 Bonus Plan and any performance-based bonus plan in a future year that applies to permanent full-time employees of the Company who are at the level of VP. Payment of any bonus to you is subject to the terms and conditions of the applicable bonus plan, and your on-target bonus under any applicable bonus plan will be 20% of the Base Salary, based on achievement of the corporate objectives under the applicable bonus plan, and your personal objectives set by the CEO in relation to the applicable bonus plan. The adoption of, terms of, funding of, and setting and evaluation of achievement of the corporate objectives is in the sole discretion of the board of directors of the Company (the “Board”). The setting and evaluation of the achievement of your personal objectives is in the sole discretion of the CEO. (c) Tax Preparation Assistance: The Company will reimburse you for reasonable tax accounting expenses as documented by third-party receipts (submitted for reimbursement no later than June 30, 2023) up to a maximum of USD$4,000 for tax filing associated with calendar year 2022. (d) Vacation Entitlement: As long as you remain a permanent employee of the Company working mainly in the United States, you will be entitled to participate in the Company’s unlimited vacation plan. Any vacation will be taken at such time or times as mutually agreed by the parties, and in compliance with the policies of the Company as amended from time to time. Failing such agreement, the Company may schedule your vacation time or times based on business considerations of the Company. Under the Company’s unlimited vacation plan, you will not accrue vacation days. Therefore, the Company will not compensate unused vacation time for any given year or upon termination of employment.

 
D-Wave Commercial Inc. 2650 E Bayshore Road Palo Alto, California USA 94303 www.dwavesys.com Page 3 of 9 (e) Medical Insurance and Other Benefits: The Company will make available to you the insured benefit plans customarily available to its US full-time employees at your level (the “Benefits”). Your participation in some of the Benefits may be mandatory in accordance with the terms and conditions of the Benefits. The terms and conditions of the Benefits, and your ability to qualify for the Benefits, will be determined by the plans or policies from time to time established, amended or purchased by the Company in its sole discretion. The Company retains the right to establish new Benefits and to eliminate, modify or alter any Benefits or benefit carriers from time to time and at any time in its sole discretion without advance notice. The terms and conditions of this Agreement will continue to apply to you despite any such changes. The Company’s obligations will not be to act as a self-insurer unless otherwise expressly stated in the terms and conditions of the applicable Benefits. The Company will, where applicable, pay premiums to an insurance carrier of its choice. All decisions regarding eligibility and coverage will be made by such insurance carrier; the Company will not bear any responsibility or liability therefore. 4. Confidentiality: (a) Access to Confidential Information: You acknowledge that in the course of performing and fulfilling your duties and responsibilities to the Company, you may be entrusted with Confidential Information, and that the disclosure of the Confidential Information to suppliers, partners, collaborators, resellers, competitors or customers of the Company or its Affiliates or to the general public will be highly detrimental to the best interests and business of the Company and its Affiliates. “Affiliates” means any entity or corporation, directly or indirectly, through one or more intermediaries, controlling, controlled by, or under common control with the Company. (b) Definition: “Confidential Information” means trade secrets and information that is not generally known to the public or that would be reasonably considered confidential and proprietary to the Company, its Affiliates and their suppliers, partners, collaborators, resellers and customers, and includes but is not limited to: (i) trade secrets, know-how, concepts, ideas whether patentable or not, methods, processes, formulae, apparatus, standards, product specifications and processing procedures; (ii) revenue, costs, pricing and other financial data; (iii) any customer or business partner information (including without limitation, names, preferences, financial information, addresses or telephone numbers); (iv) all access codes, systems software applications, software/systems source and object codes, data, documentation, program files, flow charts, operational procedures, locations of operations, merchant numbers and merchant support and verification numbers; and (v) the private affairs of the Company and its Affiliates, or any other proprietary information of the Company or its Affiliates related to their business and affairs, whether acquired in the course of your employment with the Company or incidentally. (c) Exclusions: Notwithstanding the provisions of Section 4(b), “Confidential Information” does not include information or data which: (i) is in the public domain at the date of its disclosure to you, or which thereafter enters the public domain through no fault of yours or of any other person owing a duty of confidentiality to the Company or its Affiliates (but only after it enters the public domain); or

 
D-Wave Commercial Inc. 2650 E Bayshore Road Palo Alto, California USA 94303 www.dwavesys.com Page 4 of 9 (ii) was in your possession on a non-confidential basis prior to being disclosed under this Agreement as reasonably demonstrated by your written records; provided that information which comprises part of the Confidential Information will not be included within the foregoing exceptions merely because individual parts of the information were within the public domain or were within your prior possession. (d) Use and Disclosure: You acknowledge that you will receive the Confidential Information solely for the purpose of carrying out your duties and responsibilities as an employee of the Company. Except as may be specifically required in the course of carrying out such duties and responsibilities, you will not, during the term of your employment with the Company or at any time thereafter: (i) disclose any Confidential Information to any person or entity, without the prior written consent of the Company; or (ii) use or exploit, directly or indirectly, the Confidential Information for any purpose other than the proper purposes of the Company. Despite the foregoing, if you are required by law to disclose any Confidential Information, to the extent permitted by law, you will promptly notify the Company that you may be required to disclose Confidential Information and you will consult with and cooperate with the Company in any attempt to resist or narrow such disclosure or to obtain an order or other assurance that such information will be accorded confidential treatment. Notwithstanding any disclosure required by law, the Confidential Information disclosed will, for all other purposes, continue to be treated as Confidential Information under this Agreement. (e) Return: Upon the termination of your employment with the Company for any reason, or upon the written request of the Company at any time, you will return immediately to the Company all Confidential Information then in your possession or under your control, including all written information, tapes, discs or memory devices and copies thereof including, without limitation, all papers, drawings, notes, notebooks, correspondence, records, reports, lists, photographs, memoranda, manuals, specifications, designs, devices and documents, and any other material on any medium in your possession or control pertaining to the Company. You will also return any computers, phones, keys, pass cards, identification cards or other property belonging to the Company. 5. Corporate Opportunities and Intellectual Property: (a) Opportunities: Any business opportunities related to: (i) the current business or prospective business of the Company or its Affiliates; (ii) any of the Confidential Information or any of the Property (as defined below); or (iii) any work performed by you for the Company; which become known to you during the period of your employment with the Company must be promptly and fully disclosed and made available by you to the Company, and you agree not to take or omit to take, without the prior written approval of the Company, any action if the result would be to divert from the Company or its Affiliates any such opportunity.

 
D-Wave Commercial Inc. 2650 E Bayshore Road Palo Alto, California USA 94303 www.dwavesys.com Page 5 of 9 (b) Property Ownership: You acknowledge and agree that all right, title and interest in and to any information, documents, drawings, plans, models, works, trade secrets, inventions, discoveries, methods, improvements, research materials, designs, algorithms, user interfaces, application programming interfaces, software and databases, including all Confidential Information and including all intellectual property rights associated therewith, that: (i) relate to the Company’s or its Affiliates’ business, as it may be conducted from time to time, and is made or conceived directly or indirectly by you during the course of your employment, whether or not conceived or made during your regular working hours and whether or not you are specifically instructed to make or develop the same and whether made solely, jointly or in combination with others; (ii) are made or conceived directly or indirectly by you during the course of your employment and during your regular working hours, whether or not you are specifically instructed to make or develop the same or whether made solely, jointly or in combination with others; or (iii) are made or conceived directly or indirectly by you during the course of your employment and using the Company’s or its Affiliates’ tools and equipment, whether or not conceived or made during your regular working hours and whether or not you are specifically instructed to make or develop the same and whether made solely, jointly or in combination with others; (collectively the “Property”), will be for the benefit of the Company or its Affiliates, as applicable, and will be considered to have been made under and by virtue of this Agreement and will immediately become the property of the Company or its Affiliates, as applicable. Any invention described in a patent application filed by or on behalf of you, or which is disclosed to third parties by you within one (1) year after terminating your employment with the Company which relates to your work with the Company, is rebuttably presumed to have been conceived or made during the period of your employment by the Company using the trade secrets or other intellectual property rights of the Company or its Affiliates, and you hereby assign and agree to assign the invention and all rights therein to the Company as provided by this Agreement, including any application or registration related to such invention. The assignment or offer to assign set forth in this Section 5(b) does not apply to an invention in relation to which you can clearly show by corroborating evidence that such invention was made without the use of the Company’s or its Affiliates’ trade secrets or other intellectual property rights and was made entirely on your own time, without the use of Company’s or its Affiliates’ equipment, supplies or facilities, unless (a) the invention relates (i) directly to the business of the Company or its Affiliates, or (ii) to the Company’s or its Affiliates’ actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by you for the Company or its Affiliates. (c) Assignments: You hereby assign and agree to assign to the Company your entire right, title and interest in and to any and all of the Property and to all letters patent, design patents, industrial designs, copyright, mask works, trade-marks, trade secret rights, and all other intellectual property rights, and all applications therefor which may be or may have been filed on the Property by or for you or in your name, or which may have been issued to you or for your benefit, whether filed or issued in the United States or any other country whatsoever, including the right to claim priority thereof, to file directly in the Company’s own name, to have patents grant in the Company’s own name, and to pursue damages for infringement of any such rights, including for past infringement. You further agree to execute any papers evidencing such assignment, including executing counterpart or short form assignment documents, and to fully cooperate as may be requested by the Company, at the Company’s own expense, in evidencing such assignment and in securing intellectual property rights in the Property.

 




D-Wave Commercial Inc. 2650 E Bayshore Road Palo Alto, California USA 94303 www.dwavesys.com Page 7 of 9 (i) other than in the performance of your duties and responsibilities, use any of the Company’s and its Affiliates’ trade secrets for any reason without the express written permission of the Company, including to: (1) engage in, carry on or otherwise be concerned with or have any interest in, or advise, lend money to, guarantee the debts or obligations of, permit your name, or any part thereof, to be used or employed by any person, firm, association, syndicate or corporation engaged in or concerned with a business competitive with that of the Company or its Affiliates; or (2) solicit, interfere with or endeavor to entice away from the Company or its Affiliates, accept any business from or the patronage of or enter into the employment of or render any service to, sell to or contract or attempt to contract with, any person, firm, or corporation who was, during the term of your employment, a customer or supplier of the Company or its Affiliates, or a prospective customer or supplier of the Company or its Affiliates; or (ii) for a one (1) year period following the termination of your employment with the Company, directly solicit or induce or attempt to solicit or induce any person who was employed by the Company or its Affiliates on the date of the termination of your employment, to terminate his or her employment with the Company or its Affiliates or to commence an employment or other business relationship with another entity. (c) The parties agree that the foregoing provisions are reasonable and necessary in order to protect the interests of the Company and its Affiliates. (d) You agree and acknowledge that this covenant is given for good and valuable consideration (receipt of which is hereby acknowledged) and that by reason of your unique knowledge of and association with the business of the Company and its Affiliates, the scope of this covenant as to both time and area is reasonable and commensurate with the protection of the legitimate interests of the Company and its Affiliates. Section 6 of this Agreement applies regardless of the reason for your cessation of employment from the Company, and is severable from the other provisions of this Agreement. (e) The parties agree that if a court of competent jurisdiction will limit, restrict or otherwise change the time period or the types of business referred to in this Section, then the limited, restricted or changed time period or types of business determined by such a court will, for the purposes of this Section 6, be deemed to be the original time period and/or types of business referred to in such Sections as if they were the original time period and business set out herein. 7. Resignation: You can resign from employment with the Company by providing to the Company two (2) weeks’ prior written notice of your resignation. The Company may elect, in its sole discretion, to not require that you attend work for any portion of this two (2) week notice period in which case your Salary would continue for the balance of the notice period and your benefits would, at the option of the Company, cease effective on your last day of work. 8. Employment at Will: Your employment with the Company is “at will” according to the laws of the State of Florida. As an at-will employee, you or the Company may terminate your employment at any time with or without cause and with or without notice except where applicable United States federal, State of Florida or local law provides otherwise. The Company also has sole discretion to modify the terms and conditions of your

 
D-Wave Commercial Inc. 2650 E Bayshore Road Palo Alto, California USA 94303 www.dwavesys.com Page 8 of 9 employment. No representative of the Company, other than the CEO has the authority to change the “at-will” status of any employee, and in order to be effective, the change must be in writing. 9. Irreparable Harm: You acknowledge and agree that a breach of any of the covenants of this Agreement by you may not be adequately compensated for by monetary award, and may cause irreparable harm to the Company and its Affiliates. Accordingly, you agree that in addition to all of the remedies available to the Company and its Affiliates at law or in equity, including the right to seek recovery of damages, the Company and its Affiliates will be entitled as a matter of right to apply for equitable relief (including without limitation, injunctive relief) in any court of competent jurisdiction, enjoining any threatened or actual breach, to ensure your compliance with the provisions of this Agreement. 10. Assignment and Enurement: You may not assign this Agreement, or any part of this Agreement or any of your rights under this Agreement, without the prior written consent of the Company. The Company may assign this Agreement to any other entity at any time in its sole discretion. This Agreement enures to the benefit of and is binding upon you and the Company and the respective heirs, executors, administrators, successors and permitted assigns. 11. Severability: If any provision or portion of this Agreement is determined to be invalid or unenforceable for any reason, then that provision or portion will be severed from this Agreement unless otherwise provided. The rest of this Agreement will remain in full force and effect. 12. Entire Agreement: This Agreement contains the whole agreement between you and the Company with respect to your employment with the Company, and there are no representations, warranties, collateral terms or conditions, express or implied, other than as set forth in this Agreement. This Agreement supersedes all prior agreements, negotiations, discussions, undertakings, representations, warranties and understandings, whether written or oral, express or implied, statutory or otherwise, between you and the Company. You hereby waive any right to assert a claim in tort based on any pre-contractual representations, negligent or otherwise, made by the Company. You also hereby confirm that you have not been induced to enter into this Agreement by any prior agreement, negotiation, discussion, undertaking, representation, warranty, or understanding, whether written or oral, express or implied, statutory or otherwise, between you and the Company. No change or modification of this Agreement will be valid unless it is in writing and executed by both parties. The terms and conditions of this Agreement will govern your employment with the Company, regardless of the length of employment or any changes to your position, compensation, title and regardless of whether such change is material or otherwise. 13. Notice: Any notice required or permitted to be given hereunder must be in writing and will be sufficiently given or made if delivered or sent by email or by registered mail to the address of the parties set out on page 1 hereof. Any notice so given will be deemed to have been given and to have been received on the day of delivery if it is a business day and otherwise on the next succeeding business day or, if mailed, on the third business day following the mailing thereof (excluding each day during which there exists any interruption of postal services due to strike, lockout or other cause). Addresses for notice may be changed by giving notice in accordance with this Section. 14. Non-waiver: No failure or delay by you or the Company in exercising any power or right under this Agreement will operate as a waiver of such power or right. Any consent or waiver by you or by the Company to any breach or default under this Agreement will be effective only in the specific instance and for the specific purpose for which it was given. 15. Survival of Terms: The provisions of Sections 4 to 18 of this Agreement will survive the termination of your employment and this Agreement.

 




EX-10.13 9 exhibit1013-q22023.htm EX-10.13 exhibit1013-q22023











EX-10.14 10 exhibit1014-q22023.htm EX-10.14 exhibit1014-q22023






EX-31.1 11 exhibit311-q22023.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, Alan Baratz, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of D-Wave Quantum Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: August 10, 2023 By: /s/ Alan Baratz
Alan Baratz
President and Chief Executive Officer
(Principal Executive Officer)

EX-31.2 12 exhibit312-q22023.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, John M. Markovich, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of D-Wave Quantum Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: August 10, 2023 By: /s/ John M. Markovich
John M. Markovich
Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 13 exhibit321-q22023.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of D-Wave Quantum Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan Baratz, President & Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Dated: August 10, 2023 By: /s/ Alan Baratz
President and Chief Executive Officer
(Principal Executive Officer)

EX-32.2 14 exhibit322-q22023.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of D-Wave Quantum Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John M. Markovich, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Dated: August 10, 2023 By: /s/ John M. Markovich
Chief Financial Officer
(Principal Financial and Accounting Officer)